

# SAMPLE SELECTED INDICATORS (ALL) REPORT – GPRA+ FY04

Cover Page

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

Date Report Run: Jan 06, 2004

Site where Run: DEMO SITE

Report Generated by: LASTNAME, FIRST MI

Reporting Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Indicators: Selected Indicators

Population: AI/AN Only (Classification 01)

RUN TIME (H.M.S): 2.4.58

Denominator Definitions used in this Report:

ACTIVE CLINICAL POPULATION:

1. Must reside in a community specified in the community taxonomy used for this report.
2. Must be alive during the entire time frame.
3. User defines: a) Indian/Alaska Natives Only - based on Classification of 01; b) Non AI/AN (not 01); or c) Both
4. Must have 2 visits to medical clinics in the 3 years prior to the end of the Report period. At least one visit must include: 01 General, 06 Diabetic, 10 GYN, 12 Immunization, 13 Internal Med, 20 Pediatrics, 24 Well Child, 28 Family Practice, 57 EPSDT, 70 Women's Health, 80 Urgent, 89 Evening. See User Manual for complete description of medical clinics.

USER POPULATION:

1. Definitions 1-3 above.
2. Must have been seen at least once in the 3 years prior to the end of the Report period, regardless of the clinic type.

A delimited output file called demose1  
has been placed in the public directory for your use in Excel or some  
other software package.  
See your site manager to access this file.

The following communities are included in this report:

COMMUNITY #1	COMMUNITY #2
COMMUNITY #3	COMMUNITY #4
FACILITY #1	FACILITY #2
FACILITY #3	FACILITY #4
FACILITY #5	RURAL SITE #1
URBAN SITE #1	URBAN SITE #2

**PLEASE NOTE: This is a sample Selected Indicators (All Indicators) report compiled from various sources for GPRA+ FY04 (BGP version 3.0). Some manual formatting has been done to condense the report for printing purposes. Your report may not appear exactly the way this report does.**

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Diabetes Prevalence

Denominator(s):

All User Population users. Breakdown by gender and by age groups: <15, 15-19, 20-24, 25-34, 35-44, 45-54, 55-64, >64.

Numerator(s):

Anyone diagnosed with Diabetes at any time before the end of the Report period.

Anyone diagnosed with Diabetes in the year prior to the end of the Report period.

Age is calculated at the beginning of the Report period. Diabetes diagnosis is defined as at least one diagnosis 250.00-250.93 recorded in the V POV file.

During FY 2004, continue tracking (i.e., data collection and analyses) Area age-specific diabetes prevalence rates to identify trends in the age-specific prevalence of diabetes (as a surrogate marker for diabetes incidence) for the AI/AN population.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# User pop	8,626		8,509			8,378		
# w/ any DM DX	1,118	13.0	1,020	12.0	+1.0	947	11.3	+1.7
# w/ DM DX w/in past year	815	9.4	736	8.6	+0.8	656	7.8	+1.6
# Male User pop	3,684		3,630			3,574		
# w/ any DM DX	403	10.9	373	10.3	+0.7	333	9.3	+1.6
# w/DM DX w/in past year	285	7.7	274	7.5	+0.2	232	6.5	+1.2
# Female User pop	4,942		4,879			4,804		
# w/ any DM DX	715	14.5	647	13.3	+1.2	614	12.8	+1.7
# w/ DM DX w/in past year	530	10.7	462	9.5	+1.3	424	8.8	+1.9

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Age Specific Diabetes Prevalence

	TOTAL USER POPULATION							
	Age Distribution							
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs
CURRENT REPORT PERIOD								
Total # User Pop	2,861	869	964	1,502	1,151	704	349	226
# w/ DM DX ever	15	22	58	151	277	277	189	129
% w/ DM DX ever	0.5	2.5	6.0	10.1	24.1	39.3	54.2	57.1
# w/DM DX in past yr	6	13	31	112	173	218	161	101
% w/DM DX in past yr	0.2	1.5	3.2	7.5	15.0	31.0	46.1	44.7
PREVIOUS YEAR PERIOD								
Total # User Pop	2,865	879	969	1,469	1,127	673	330	197
# w/ DM DX ever	15	17	48	139	258	264	167	112
% w/ DM DX ever	0.5	1.9	5.0	9.5	22.9	39.2	50.6	56.9
# w/DM DX in past yr	7	11	30	88	179	207	133	81
% w/DM DX in past yr	0.2	1.3	3.1	6.0	15.9	30.8	40.3	41.1
CHANGE FROM PREV YR %								
w/ DM DX ever	+0.0	+0.6	+1.1	+0.6	+1.2	+0.1	+3.5	+0.2
w/DM DX in past yr	-0.0	+0.2	+0.1	+1.5	-0.9	+0.2	+5.8	+3.6
BASELINE REPORT PERIOD								
Total # User Pop	2,878	849	958	1,476	1,071	647	304	195
# w/ DM DX ever	12	16	40	140	245	239	147	108
% w/ DM DX ever	0.4	1.9	4.2	9.5	22.9	36.9	48.4	55.4
# w/DM DX in past yr	6	11	23	89	160	181	114	72
% w/DM DX in past yr	0.2	1.3	2.4	6.0	14.9	28.0	37.5	36.9
CHANGE FROM BASE YR %								
w/ DM DX ever	+0.1	+0.6	+1.8	+0.6	+1.2	+2.4	+5.8	+1.7
w/DM DX in past yr	+0.0	+0.2	+0.8	+1.4	+0.1	+3.0	+8.6	+7.8

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Age Specific Diabetes Prevalence

	MALE USER POPULATION							
	Age Distribution							
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs
CURRENT REPORT PERIOD								
Total MALE User Pop	1,432	392	342	581	482	269	105	81
# w/ DM DX ever	5	10	20	57	117	97	59	38
% w/ DM DX ever	0.3	2.6	5.8	9.8	24.3	36.1	56.2	46.9
# w/DM DX in past yr	2	3	10	46	72	73	49	30
% w/DM DX in past yr	0.1	0.8	2.9	7.9	14.9	27.1	46.7	37.0
PREVIOUS YEAR PERIOD								
Total MALE User Pop	1,415	397	354	576	461	251	108	68
# w/ DM DX ever	6	8	17	48	105	93	61	35
% w/ DM DX ever	0.4	2.0	4.8	8.3	22.8	37.1	56.5	51.5
# w/DM DX in past yr	4	4	14	30	78	72	45	27
% w/DM DX in past yr	0.3	1.0	4.0	5.2	16.9	28.7	41.7	39.7
CHANGE FROM PREV YR %								
w/ DM DX ever	-0.1	+0.5	+1.0	+1.5	+1.5	-1.0	-0.3	-4.6
w/DM DX in past yr	-0.1	-0.2	-1.0	+2.7	-2.0	-1.5	+5.0	-2.7
BASELINE REPORT PERIOD								
Total MALE User Pop	1,428	376	353	586	426	235	103	67
# w/ DM DX ever	5	9	12	46	97	74	57	33
% w/ DM DX ever	0.4	2.4	3.4	7.8	22.8	31.5	55.3	49.3
# w/DM DX in past yr	4	6	11	29	65	54	41	22
% w/DM DX in past yr	0.3	1.6	3.1	4.9	15.3	23.0	39.8	32.8
CHANGE FROM BASE YR %								
w/ DM DX ever	-0.0	+0.2	+2.4	+2.0	+1.5	+4.6	+0.9	-2.3
w/DM DX in past yr	-0.1	-0.8	-0.2	+3.0	-0.3	+4.2	+6.9	+4.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Age Specific Diabetes Prevalence

	FEMALE USER POPULATION							
	Age Distribution							
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs
CURRENT REPORT PERIOD								
Total FEMALE User Pop	1,429	477	622	921	669	435	244	145
# w/ DM DX ever	10	12	38	94	160	180	130	91
% w/ DM DX ever	0.7	2.5	6.1	10.2	23.9	41.4	53.3	62.8
# w/DM DX in past yr	4	10	21	66	101	145	112	71
% w/DM DX in past yr	0.3	2.1	3.4	7.2	15.1	33.3	45.9	49.0
PREVIOUS YEAR PERIOD								
Total FEMALE User Pop	1,450	482	615	893	666	422	222	129
# w/ DM DX ever	9	9	31	91	153	171	106	77
% w/ DM DX ever	0.6	1.9	5.0	10.2	23.0	40.5	47.7	59.7
# w/DM DX in past yr	3	7	16	58	101	135	88	54
% w/DM DX in past yr	0.2	1.5	2.6	6.5	15.2	32.0	39.6	41.9
CHANGE FROM PREV YR %								
w/ DM DX ever	+0.1	+0.6	+1.1	+0.0	+0.9	+0.9	+5.5	+3.1
w/DM DX in past yr	+0.1	+0.6	+0.8	+0.7	-0.1	+1.3	+6.3	+7.1
BASELINE REPORT PERIOD								
Total FEMALE User Pop	1,450	473	605	890	645	412	201	128
# w/ DM DX ever	7	7	28	94	148	165	90	75
% w/ DM DX ever	0.5	1.5	4.6	10.6	22.9	40.0	44.8	58.6
# w/DM DX in past yr	2	5	12	60	95	127	73	50
% w/DM DX in past yr	0.1	1.1	2.0	6.7	14.7	30.8	36.3	39.1
CHANGE FROM BASE YR %								
w/ DM DX ever	+0.2	+1.0	+1.5	-0.4	+1.0	+1.3	+8.5	+4.2
w/DM DX in past yr	+0.1	+1.0	+1.4	+0.4	+0.4	+2.5	+9.6	+9.9

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

Diabetes: Glycemic Control

## Denominator(s):

All User Population patients diagnosed with diabetes at least 1 year prior to the end of the Report period.

GPRA Denominator. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Active Adult Diabetic patients, defined by meeting the following criteria:

1) who are 19 or older at the beginning of the Report period, 2) whose first ever DM diagnosis occurred at least one year prior to the end of the Report period; 3) who had at least 2 DM related visits ever, 4) at least one encounter with DM POV in a primary clinic with a primary provider during the year prior to the end of the Report period; and 5) never have had a creatinine value greater than 5. (HEDIS-based definition)

## Numerator(s):

GPRA Numerator: Number of patients with a Hemoglobin A1c documented in year prior to the end of Current Report period, regardless of result.

Very Poor Control. Patients with HgA1c equal to or greater than ( $\geq$ ) 12.

Poor Control. Patients with HgA1c greater than ( $>$ ) 9.5 or less than ( $<$ ) 12.

GPRA Numerator: Poor Control. Patients with HgA1c greater than ( $>$ ) 9.5.

Fair Control. Patients with HgA1c equal to or greater than ( $\geq$ ) 8 and less than or equal to ( $\leq$ ) 9.5.

Good Control. Patients with HgA1c equal to or greater than ( $\geq$ ) 7 and less than ( $<$ ) 8.

GPRA Numerator: Ideal Control. Patients with HgA1c less than ( $<$ ) 7.

Without result. Patients with HgA1c documented but no value.

First Purpose of Visit 250.00-250.93 recorded in the V POV file at least one year prior to the end of the Report period. Counts most recent HgA1c test in the year prior to the end of the Report period. HgA1c defined as: CPT 83036; LOINC taxonomy; or site-defined taxonomy DM AUDIT HGB A1C TAX. Without result is defined as HgA1c documented but with no value.

During FY 2004, establish the baseline of patients with diagnosed diabetes that have poor glycemic control (defined as HgA1c  $>$  9.5).

During FY 2004, increase the proportion of patients with diagnosed diabetes that have demonstrated improved glycemic control (defined as HgA1c  $<$  7).

HgA1c documented: IHS FY 2003 Performance: 75%; HP 2010 Goal: 50%

Glycemic Control ( $<$ 7): IHS FY 2002 Performance: 25%; IHS FY 2003 Performance: 28%; IHS 2010 Goal: 40%

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Diabetes: Glycemic Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX > 1 yr prior to report end date	981		919			833		
# w/HgbA1c done w/ or w/o result	633	64.5	617	67.1	-2.6	517	62.1	+2.5
# w/HgbA1c =>12	23	2.3	35	3.8	-1.5	72	8.6	-6.3
# w/HgbA1c >9.5 and < 12	118	12.0	123	13.4	-1.4	137	16.4	-4.4
# w/HgbA1c => 8 & =< 9.5	139	14.2	128	13.9	+0.2	91	10.9	+3.2
# w/HgbA1c=>7 & < 8	127	12.9	94	10.2	+2.7	82	9.8	+3.1
# w/HgbA1c < 7	226	23.0	236	25.7	-2.6	135	16.2	+6.8
# w/HgbA1c w/o Result	0	0.0	1	0.1	-0.1	0	0.0	+0.0
Active Diabetic Pts (GPRA Denominator)	645		607			545		
# w/HgbA1c done w/ or w/o result (GPRA)	582	90.2	555	91.4	-1.2	490	89.9	+0.3
# w/HgbA1c =>12 (GPRA)	21	3.3	28	4.6	-1.4	64	11.7	-8.5
# w/HgbA1c >9.5 and < 12 (GPRA)	105	16.3	107	17.6	-1.3	131	24.0	-7.8
# w/HgbA1c => 8 & =< 9.5	127	19.7	120	19.8	-0.1	89	16.3	+3.4
# w/HgbA1c=>7 & < 8	122	18.9	89	14.7	+4.3	81	14.9	+4.1
# w/HgbA1c < 7 (GPRA)	207	32.1	210	34.6	-2.5	125	22.9	+9.2
# w/HgbA1c w/o Result	0	0.0	1	0.2	-0.2	0	0.0	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Diabetes: Glycemic Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Adult Diabetic Patients	487		419			360		
# w/HgbA1c done w/ or w/o result	453	93.0	400	95.5	-2.4	329	91.4	+1.6
# w/HgbA1c =>12	16	3.3	25	6.0	-2.7	45	12.5	-9.2
# w/HgbA1c >9.5 and < 12	90	18.5	88	21.0	-2.5	99	27.5	-9.0
# w/HgbA1c => 8 & =< 9.5	108	22.2	95	22.7	-0.5	67	18.6	+3.6
# w/HgbA1c=>7 & < 8	98	20.1	59	14.1	+6.0	45	12.5	+7.6
# w/HgbA1c < 7	141	29.0	132	31.5	-2.6	73	20.3	+8.7
# w/HgbA1c w/o Result	0	0.0	1	0.2	-0.2	0	0.0	+0.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Diabetes: Blood Pressure Control

Denominator(s):

All User Population patients diagnosed with diabetes at least 1 year prior to the end of the Report period.

GPRA Denominator. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Active Adult Diabetic patients, defined by meeting the following criteria: 1) who are 19 or older at the beginning of the Report period, 2) whose first ever DM diagnosis occurred at least one year prior to the end of the Report period; 3) who had at least 2 DM related visits ever, 4) at least one encounter with DM POV in a primary clinic with a primary provider during the year prior to the end of the Report period; and 5) never have had a creatinine value greater than 5. (HEDIS-based definition)

Numerator(s):

Patients with Blood Pressure documented during year prior to end of Report period.

GPRA Numerator. Patients with controlled BP, defined as < 130/80, i.e., the mean systolic value is less than 130 AND the mean diastolic value is less than 80.

Patients with BP that is not controlled.

First DM Purpose of Visit 250.00-250.93 recorded in the V POV file at least one year prior to the end of the Report period. GPRA+ uses mean of last 3 Blood Pressures documented on non-ER visits in the year prior to the end of the Report period. If 3 BPs are not available, uses mean of

last 2 non-ER BPs. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not BOTH meet the criteria for controlled, then the value is considered not controlled.

During FY 2004, increase the proportion of patients with diagnosed diabetes that have achieved blood pressure control (defined as <130/80) by 2% over FY 2003 level.

Controlled BP: IHS FY 2002 Performance: 36%; IHS FY 2003 Performance: 37%  
IHS 2010 Goal: 50%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX	981		919			833		
# w/ BPs documented	681	69.4	646	70.3	-0.9	572	68.7	+0.8
# w/controlled BP < 130/80	396	40.4	377	41.0	-0.7	322	38.7	+1.7
# w/Not controlled BP	285	29.1	269	29.3	-0.2	250	30.0	-1.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Diabetes: Blood Pressure Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Pts (GPRA Denominator)	645		607			545		
# w/ BPs documented	606	94.0	571	94.1	-0.1	513	94.1	-0.2
# w/Controlled BP < 130/80 (GPRA)	353	54.7	329	54.2	+0.5	286	52.5	+2.3
# w/Not controlled BP	253	39.2	242	39.9	-0.6	227	41.7	-2.4
Active Adult Diabetic Patients	487		419			360		
# w/ BPs documented	444	91.2	386	92.1	-1.0	342	95.0	-3.8
# w/Controlled BP < 130/80	263	54.0	231	55.1	-1.1	191	53.1	+0.9
# w/Not controlled BP	181	37.2	155	37.0	+0.2	151	41.9	-4.8

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

Diabetes: Lipids Assessment

## Denominator(s):

All User Population patients diagnosed with diabetes at least 1 year prior to the end of the Report period.

GPRA Denominator. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Active Adult Diabetic patients, defined by meeting the following criteria:

1) who are 19 or older at the beginning of the Report period, 2) whose first ever DM diagnosis occurred at least one year prior to the end of the Report period; 3) who had at least 2 DM related visits ever, 4) at least one encounter with DM POV in a primary clinic with a primary provider during the year prior to the end of the Report period; and 5) never have had a creatinine value greater than 5. (HEDIS-based definition)

## Numerator(s):

Patients who have had either a LIPID PROFILE or an LDL, an HDL and Triglyceride (TG) (all three) in the year prior to the end of the Report period.

GPRA Numerator. Patients with LDL completed in the prior year, regardless of result.

Patients with LDL results less than (<) 130.

A: Patients with LDL results less than or equal to (<=) 100.

B: Patients with LDL results 101-129.

First DM Purpose of Visit 250.00-250.93 recorded in the V POV file at least one year prior to the end of the Report period. For Numerators 1 and 2, counts all Y instances reported, regardless of the results of the measurement. For each test, finds the last test done in year prior to end of Report period. Test Definitions: 1) Lipid Profile: CPT 80061; LOINC taxonomy; site defined taxonomy DM AUDIT LIPID PROFILE TAX. 2) LDL: CPT 83721; LOINC taxonomy; site defined taxonomy DM AUDIT LDL CHOLESTEROL TAX. 3) HDL: CPT 83718; LOINC taxonomy; site-defined taxonomy DM AUDIT HDL TAX. 4) Triglyceride: 84478; LOINC taxonomy; site defined taxonomy DM AUDIT TRIGLYCERIDE TAX.

During FY 2004, increase the proportion of patients with diagnosed diabetes assessed for dyslipidemia by 2% over FY 2003 level.

Patients Assessed: IHS FY 2002 Performance: 44%; IHS FY 2003 Performance: 47.5% HP 2010 Goal: 70%

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Diabetes: Lipids Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX	981		919			833		
# w/Lipid Profile OR TG & HDL & LDL recorded	310	31.6	349	38.0	-6.4	324	38.9	-7.3
# w/ LDL done	151	15.4	175	19.0	-3.6	92	11.0	+4.3
# w/LDL < 130	90	9.2	143	15.6	-6.4	59	7.1	+2.1
A. # of patients w/LDL result =< 100	62	6.3	94	10.2	-3.9	36	4.3	+2.0
B. # w/LDL 101-129	28	2.9	49	5.3	-2.5	23	2.8	+0.1
Active Diabetic Pts (GPRA Denominator)	645		607			545		
# w/Lipid Profile OR TG & HDL & LDL recorded	285	44.2	315	51.9	-7.7	305	56.0	-11.8
# w/ LDL done (GPRA)	136	21.1	151	24.9	-3.8	86	15.8	+5.3
# w/LDL < 130	81	12.6	124	20.4	-7.9	55	10.1	+2.5
A. # of patients w/LDL result =< 100	58	9.0	84	13.8	-4.8	33	6.1	+2.9
B. # w/LDL 101-129	23	3.6	40	6.6	-3.0	22	4.0	-0.5
Active Adult Diabetic Patients	487		419			360		
# w/Lipid Profile OR TG & HDL & LDL recorded	196	40.2	202	48.2	-8.0	199	55.3	-15.0
# w/ LDL done	97	19.9	91	21.7	-1.8	53	14.7	+5.2
# w/LDL < 130	58	11.9	77	18.4	-6.5	35	9.7	+2.2
A. # of patients w/LDL result =< 100	42	8.6	51	12.2	-3.5	24	6.7	+2.0
B. # w/LDL 101-129	16	3.3	26	6.2	-2.9	11	3.1	+0.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Diabetes: Nephropathy Assessment

## Denominator(s):

All User Population patients diagnosed with diabetes at least 1 year prior to the end of the Report period.

GPRA Denominator. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Active Adult Diabetic patients, defined by meeting the following criteria: 1) who are 19 or older at the beginning of the Report period, 2) whose first ever DM diagnosis occurred at least one year prior to the end of the Report period; 3) who had at least 2 DM related visits ever, 4) at least one encounter with DM POV in a primary clinic with a primary provider during the year prior to the end of the Report period; and 5) never have had a creatinine value greater than 5. (HEDIS-based definition)

## Numerator(s):

GPRA Numerator. Total patients with nephropathy assessment

A: Patients with Estimated GFR with result in prior year.

B: Patients with positive urine protein test or microalbuminuria test, regardless of result, (if negative urine protein) done in year prior to the end of the Report period.

First DM Purpose of Visit 250.00-250.93 recorded in the V POV file at least one year prior to the end of the Report period. A: patients with any value in VXYZ Est GFR. B: GPRA+ searches for last microalbuminuria test done in year prior to end of Report period, regardless of result (positive or negative). If none found, searches for last urine protein test with positive (Y) value in same time period. Positive value for urine protein is defined as: 1) First character is P or p; 2) Contains a + sign; 3)

Contains a > symbol; 4) numeric value (if the result is a number) is > (greater than) 29. 1) Urine protein defined as: LOINC taxonomy; site defined taxonomy DM AUDIT URINE PROTEIN TAX. 2) Microalbuminuria defined as: CPT codes 82043, 82044; LOINC taxonomy; site defined taxonomy DM AUDIT MICROALBUMINURIA TAX

During FY 2004, increase the proportion of patients with diagnosed diabetes assessed for nephropathy by 2% over FY 2003 level.

Assessment: IHS FY 2002 Performance: 35%; IHS FY 2003 Performance: 37.5%; IHS 2010 Goal: 70%

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Diabetes: Nephropathy Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX	981		919			833		
# w/ Nephropathy assessment	134	13.7	133	14.5	-0.8	130	15.6	-1.9
A. Pts w/estimated GFR with result	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/any Microalbuminuria or positive Urine value	134	13.7	133	14.5	-0.8	130	15.6	-1.9
Active Diabetic Pts (GPRA Denominator)	645		607			545		
# w/ Nephropathy assessment (GPRA)	123	19.1	124	20.4	-1.4	118	21.7	-2.6
A. Pts w/estimated GFR w/result	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/any Microalbuminuria or positive Urine value	123	19.1	124	20.4	-1.4	118	21.7	-2.6
Active Adult Diabetic Patients	487		419			360		
# w/ Nephropathy assessment	91	18.7	82	19.6	-0.9	83	23.1	-4.4
A. Pts w/estimated GFR with result	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/any Microalbuminuria or positive Urine value	91	18.7	82	19.6	-0.9	83	23.1	-4.4

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

#### Diabetic Retinopathy

##### Denominator(s):

All User Population patients diagnosed with diabetes at least 1 year prior to the end of the Report period.

GPRA Denominator. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Active Adult Diabetic patients, defined by meeting the following criteria:

1) who are 19 or older at the beginning of the Report period, 2) whose first ever DM diagnosis occurred at least one year prior to the end of the Report period; 3) who had at least 2 DM related visits ever, 4) at least one encounter with DM POV in a primary clinic with a primary provider during the year prior to the end of the Report period; and 5) never have had a creatinine value greater than 5. (HEDIS-based definition)

##### Numerator(s):

Patients receiving any retinal screening in the year prior to the end of the Report period, or a documented refusal of a diabetic eye exam; defined as: diabetic eye exam; or a Non-DNKA visit to an optometrist or ophthalmologist; or a Non-DNKA visit to ophthalmology, optometry, or tele-ophthalmology retinal screening clinics.

A: Patients receiving diabetic retinal exam (or documented refusal) in prior year.

B: Patients receiving other eye exams in year prior to the end of Report period, defined as: Non-DNKA visit to ophthalmology, optometry clinics, or Non-DNKA visit to an optometrist or ophthalmologist.

GPRA+ searches for the first instance of ANY of: 1) diabetic eye exam or documented refusal: VExam code 03; 2) NON-DNKA visit to an optometrist or ophthalmologist (Provider codes 24, 79, 08); 3) Non-DNKA visit to ophthalmology, optometry, or tele-ophthalmology retinal screening clinics (clinic codes 17, 18, 64, A2); 4) CPT codes 92250, 92012, 92014, 92015, 92004 or 92002. Diabetic retinal exam defined as clinic code A2 Diabetic Retinopathy or Exam code 03 Diabetic Eye Exam or Refusal Exam 03.

During FY 2004, increase the proportion of patients with diagnosed diabetes who receive an annual diabetic retinal examination at designated sites by 3% over the FY 2003 rate. NOTE: The GPRA indicator reported at the national level only applies to a few test sites for FY04. This indicator is included here because all sites are expected to report on this indicator beginning in FY05. The numerator is currently defined very broadly for retinal screening.

Eye Exam: IHS FY 2003 Performance: 49%; IHS 2010 Goal: TBD

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Diabetic Retinopathy (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX	981		919			833		
# w/any Retinal screening	349	35.6	316	34.4	+1.2	245	29.4	+6.2
A. # w/ Diabetic Retinal exam or refusal	32	3.3	26	2.8	+0.4	5	0.6	+2.7
B. # w/Other Eye exams	317	32.3	290	31.6	+0.8	240	28.8	+3.5
Active Diabetic Pts GPRA Denominator	645		607			545		
# w/any Retinal screening (GPRA)	316	49.0	272	44.8	+4.2	221	40.6	+8.4
A. # w/ Diabetic Retinal Exam or refusal	27	4.2	11	1.8	+2.4	3	0.6	+3.6
B. # w/Other Eye Exams	289	44.8	261	43.0	+1.8	218	40.0	+4.8
Active Adult Diabetic Patients	487		419			360		
# w/any Retinal screening	231	47.4	175	41.8	+5.7	144	40.0	+7.4
A. # w/ Diabetic Retinal Exam	21	4.3	8	1.9	+2.4	2	0.6	+3.8
B. # w/Other Eye exams	210	43.1	167	39.9	+3.3	142	39.4	+3.7

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Diabetes and Mental Health

Denominator(s):

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Numerator(s):

Patients screened for or counseled about depression in the year prior to the end of the Report period.

Patients with a diagnosis of depressive, anxiety and/or adjustment disorders during year prior to end of Report period.

Diabetes diagnosis defined as POV 250.00-250.93. Screening and counseling are defined as: POV 79.0; or as any national patient education codes containing "DEP-". Depressive, anxiety and/or adjustment disorders diagnoses are defined as at least two visits with POV 296.\*, 300.\*, 301.13, 308.3, 309.\*, 311.\* or BHS codes 14, 15, 18, 24 in the year prior to end of Report period.

Increase the proportion of diabetic patients screened for depressive, anxiety and/or adjustment disorders.

No stated target.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Pts	645		607			545		
# screened for or counseled about depression	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# w/depression diagnosis	119	18.4	104	17.1	+1.3	78	14.3	+4.1

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Diabetes: Access to Dental Services

Denominator(s):

GPRA Denominator: Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever

Numerator(s):

Patients with documented dental visit during year prior to end of Report period.

Searches for V Dental ADA codes 0000 or 0190 or VExam 30.

During FY 2004, increase the proportion of patients with diagnosed diabetes who obtain access to dental services by 2% over the FY 2003 level.

IHS FY 2002 Performance: 36%; IHS FY 2003 Performance: 36%; HP 2010 Goal: 75%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Pts	645		607			545		
# w/dental visit in past yr	170	26.4	159	26.2	+0.2	152	27.9	-1.5

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Access to Dental Services

Denominator(s):

GPRA Denominator: All patients in the User Population.

Numerator(s):

Patients with documented dental visit during year prior to end of Report period.

Searches for V Dental ADA codes 0000 or 0190 or VExam 30.

During FY 2004, maintain the proportion of patients that obtain access to dental services at the FY 2003 level.

IHS FY 2002 Performance: 25%; IHS FY 2003 Performance: 25%; IHS 2010 Goal: 40%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# User Population	8,626		8,509			8,378		
# w/dental visit in past year	1,678	19.5	1,623	19.1	+0.4	1,683	20.1	-0.6

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Dental Sealants

Denominator(s):

No denominator. This indicator is a total count only, not a percentage.

Numerator(s):

The total number of dental sealants during the year prior to the end of the Report period.

Age of the patient is calculated at the beginning of the Report period. Sealants defined as V Dental ADA code 1351.

During FY 2004, maintain the number of sealants placed per year in patients at the FY 2003 level.

IHS FY 2002 Performance: 227,945; IHS FY 2003 Performance: TBD

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR	BASE PERIOD	%	CHG from BASE
Total # of Sealants documented (GPRA Denominator)	1,592		895		+697	1,384		+208
# Dental Sealants documented < 12	985	61.9	618	69.1	+367	776	56.1	+209
# Dental Sealants documented 12-18	494	31.0	203	22.7	+291	565	40.8	-71
# Dental Sealants documented >18	113	7.1	74	8.3	+39	43	3.1	+70

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Adult Immunizations: Influenza

Denominator(s):

All Active Clinical patients ages 50 or older.

A: All Active Clinical patients ages 50-64.

B: GPRA Denominator. All Active Clinical patients ages 65 and older.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

All User Population patients ages 50 or older.

A: All User Population patients ages 50-64.

B: All User Population patients ages 65 and older.

Numerator(s):

Patients with Influenza vaccine documented in the year prior to the end of the Report period, including refusals.

Age of the patient is calculated at the beginning of the Report period. Influenza vaccine defined as: 1) Immunization (CVX) codes: 88-Influenza Virus Vaccine, NOS; 15 Inf Virus Vac SV; 16 Inf Virus Vac WV; 111 Inf Virus Vac Intranasal; 2) POV: V04.8 or V06.6; 3) CPT: 90655, 90657-90660, 90724; 4) ICD Procedure code: 99.52; 5) Refusal Immunization 88, 111, 15, 16.

In FY 2004, maintain the FY 2003 influenza vaccination rate among non-institutionalized adults age 65 years and older.

>65 Vaccine Rate: IHS FY 2002 Performance: 51%; IHS FY 2003 Performance: 51%; HP 2010 Goal: 90%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients ages 50 or older	665		610			573		
Total # w/Flu vaccine documented	341	51.3	304	49.8	+1.4	276	48.2	+3.1
A. Active Clinical Patients ages 50-64	487		456			432		
Total # w/Flu vaccine documented	230	47.2	206	45.2	+2.1	184	42.6	+4.6
B. Active Clinical Patients 65 and older (GPRA Denominator)	178		154			141		
Total # w/Flu vaccine documented (GPRA)	111	62.4	98	63.6	-1.3	92	65.2	-2.9

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Adult Immunizations: Influenza (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Pts	645		607			545		
Total # w/Flu vaccine documented	396	61.4	377	62.1	-0.7	342	62.8	-1.4
# User Population 50 and older	871		800			756		
Total # w/Flu vaccine documented	352	40.4	312	39.0	+1.4	280	37.0	+3.4
A. # User Population ages 50-64	645		603			561		
Total # w/Flu vaccine documented	238	36.9	211	35.0	+1.9	185	33.0	+3.9
B. # User Population 65 and older	226		197			195		
Total # w/Flu vaccine documented	114	50.4	101	51.3	-0.8	95	48.7	+1.7

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Adult Immunizations: Pneumovax

Denominator(s):

GPRA Denominator: All Active Clinical patients ages 65 or older. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.  
All User Population patients ages 65 and older at beginning of Report period.

Numerator(s):

Patients with Pneumovax vaccine documented at any time before the end of the Report period.  
Diabetic patients with pneumovax documented in past five years.

Age of the patient is calculated at the beginning of the Report period.  
Pneumovax definitions: 1) Immunization codes: 33 Pneumo Polysaccharide; 100 Pneumo Conjugate; 109 Pneumo NOS; 2) POV: V06.6; V03.89, V03.82; 3) V Procedure: 99.55; 4) CPT: 90669, 90732; 5) Refusal Immunization 33, 100, 109.

In FY 2004, maintain the FY 2003 rate for pneumococcal vaccination levels among non-institutionalized adult patients age 65 years and older.

IHS FY 2002 Performance: 64%; IHS FY 2003 Performance: 65%; HP 2010 Goal: 90%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts ages 65 & older (GPRA Denominator)	178		154			141		
Total # w/Pneumovax documented (GPRA)	142	79.8	122	79.2	+0.6	108	76.6	+3.2
Active Diabetic Pts	645		607			545		
Total # w/Pneumovax documented	520	80.6	485	79.9	+0.7	448	82.2	-1.6
Total # w/Pneumovax documented in past 5 yrs	268	41.6	288	47.4	-5.9	261	47.9	-6.3
# User Population ages 65 & older	226		197			195		
Total # w/Pneumovax documented	150	66.4	132	67.0	-0.6	125	64.1	+2.3

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Women's Health: Pap Smear Rates

Denominator(s):

GPRA Denominator: Female Active Clinical patients ages 21 through 64 without documented history of Hysterectomy.

Female User Population patients ages 21 through 64 without a documented history of Hysterectomy.

Numerator(s):

Patients with a Pap Smear documented in the three years prior to end of Report period, including Refusals.

A: Patients with documented refusal.

Age of the patient is calculated at the beginning of the Report period. The difference between the age range 18-64 in the definition and 21-64 in the logic is because GPRA+ looks back 3 years for a test, i.e., when a patient who was 21 at the beginning of the Report period would have been 18. Hysterectomy defined as V Procedure: 68.3, 68.7, 68.9 or CPT 58550-54; 58150-58294. Pap Smear definitions: 1) V Lab: PAP SMEAR; 2) POV: V76.2-SCREEN MAL NEOP-CERVIX; V72.3 - GYNECOLOGIC EXAMINATION; 3) V Procedure: 91.46; 4) V CPT: 88141-88167; 5) Womens Health: procedure called Pap Smear; 6) LOINC taxonomy; 7) site-defined taxonomy BGP GPRA PAP SMEAR; 8) Refusal Exam 15 (Pelvic) or XYZ Test Pap Smear.

During FY 2004, maintain the proportion of eligible women patients who have had a Pap screen within the previous three years at the FY 2003 levels.

IHS FY 2002 Performance: 62%; IHS FY 2003 Performance: 61%; IHS 2010 Goal: 90%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical 21-64 years (GPRA Denominator)	1,956		1,972			1,932		
# w/Pap Smear recorded w/in 3 years (GPRA)	1,330	68.0	1,341	68.0	-0.0	1,300	67.3	+0.7
A. # Refusals w/ % of Total Pap	1	0.1	0	0.0	+0.1	1	0.1	-0.0
# Female User Pop 21-64 years	2,585		2,535			2,471		
# w/Pap Smear recorded w/in 3 years	1,384	53.5	1,392	54.9	-1.4	1,356	54.9	-1.3
A. # Refusals w/ % of Total Pap	1	0.1	0	0.0	+0.1	1	0.1	-0.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Women's Health: Mammogram Rates

Denominator(s):

GPRA Denominator: Female Active Clinical patients ages 52 through 64 without a documented history of bilateral mastectomy. Female User Population patients ages 52 through 64 without a documented history of bilateral mastectomy.

Numerator(s):

All patients who had a Mammogram documented in the two years prior to the end of the Report period, including documented refusals.

A: Number of patients with documented refusal.

Age of the patient is calculated at the beginning of the Report period. The difference between the age range in the indicator definition and the logic is because GPRA+ looks back 2 years for a procedure; i.e., when a patient who was 52 in the Report period would have been 50. Bilateral mastectomy defined as: ICD Operation codes: 85.42; 85.44; 85.46; 85.48 Screening Mammogram definitions: 1) V Radiology or V CPT: 76090 Mammogram; unilateral; 76091 Mammogram; bilateral; 76092 Mammogram; screening; 2) POV: V76.11 screening mammogram for high risk patient; V76.12 other screening mammogram; 3) V Procedure: 87.37Other Mammography; 87.36 Xerography of breast; 87.35 soft tissue X-ray of thorax, contrast radiogram of mammary ducts; 4) Womens Health: SCREENING MAMMOGRAM, MAMMOGRAM DX BILAT, MAMMOGRAM DX UNILAT; 5) Refusal Procedure codes 87.35-87.37

During FY 2004, maintain the proportion of eligible women patients who have had mammography screening within the last 2 years at the FY 2003 rate.

IHS FY 2002 Performance: 42%; IHS FY 2003 Performance: 40%; IHS 2010 Goal: 70%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Active Clinical Women 52-64 years (GPRA Denominator)	274		250			233		
# w/Mammogram recorded w/in 2 years (GPRA)	122	44.5	116	46.4	-1.9	101	43.3	+1.2
A. # Refusals w/ % of Total Mammograms	0	0.0	1	0.9	-0.9	2	2.0	-2.0
# User Pop Women 52-64 years	345		314			283		
# w/Mammogram recorded w/in 2 years	124	35.9	121	38.5	-2.6	102	36.0	-0.1
A. # Refusals w/ % of total Mammograms	0	0.0	1	0.8	-0.8	2	2.0	-2.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*  
 DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003  
 Previous Year Period: Oct 01, 2001 to Sep 30, 2002  
 Baseline Period: Oct 01, 2000 to Sep 30, 2001

Colorectal Cancer Screening

Denominator(s):

All Active Clinical patients ages 52 and older.  
 All User Population patients age 52 and older.

Numerator(s):

Patients who have had ANY CRC screening, defined as any of the following:  
 1) Fecal Occult Blood test or Rectal Exam in the 2 years prior to the end of the Report period; 2) flexible sigmoidoscopy or double contrast barium enema in the past 5 years; or 3) colonoscopy in the past 10 years.  
 A: Patients with Fecal Occult Blood test (FOBT) in the past two years.  
 B: Patients with Rectal Exam in the past two years.

Age is calculated at the beginning of the Report period. Screening defined as: 1. Fecal Occult Blood XYZ test (FOBT): CPT 82274, G0107, LOINC taxonomoy, or site defined taxonomy BGP GPRA FOB TESTS; 2. Rectal screen: V76.41; V Procedure 48.24-29, 89.34 Rectal Exam; V Exam 14; 3. Flexible Sigmoidoscopy: V Procedure 45.24; CPT 45330-45345; 4. Rigid proctosigmoidoscopy: V Procedure 48.21-23; CPT 45300 45327; 5. Double contrast barium enema: Procedure 87.64 (lower GI); CPT or VRad: 74270-74280; 6. Colonoscopy: V76.51 Colon screening; V Procedure 45.21, 45.22, 45.23, 45.25 ; CPT 45355-45387; 45325 (old)

For FY04, increase the proportion of patients ages 52 and older who have had screening for Colorectal Cancer.

IHS FY 2004 Goal: TBD.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients								
52 and older	577		521			485		
# w/screening	113	19.6	125	24.0	-4.4	96	19.8	-0.2
A. # w/FOB test in past 2 yrs	17	2.9	27	5.2	-2.2	23	4.7	-1.8
B. # w/ rectal exam in past 2 yrs	90	15.6	94	18.0	-2.4	73	15.1	+0.5

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Colorectal Cancer Screening (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Male Active Clinical 52 and older	169		152			139		
# w/screening	8	4.7	11	7.2	-2.5	11	7.9	-3.2
A. # w/FOB test in past 2 yrs	5	3.0	7	4.6	-1.6	5	3.6	-0.6
B. # w/ rectal exam in past 2 yrs	0	0.0	2	1.3	-1.3	3	2.2	-2.2
Female Active Clinical 52 and older	408		369			346		
# w/screening	105	25.7	114	30.9	-5.2	85	24.6	+1.2
A. # w/FOB test in past 2 yrs	12	2.9	20	5.4	-2.5	18	5.2	-2.3
B. # w/ rectal exam in past 2 yrs	90	22.1	92	24.9	-2.9	70	20.2	+1.8
Total User Population 52 and older	753		681			635		
# w/screening	114	15.1	130	19.1	-4.0	97	15.3	-0.1
A. # w/FOB test in past 2 yrs	17	2.3	28	4.1	-1.9	23	3.6	-1.4
B. # w/ rectal exam in past 2 yrs	91	12.1	99	14.5	-2.5	74	11.7	+0.4
Total Male User Pop 52 and older	246		224			212		
# w/screening	8	3.3	11	4.9	-1.7	11	5.2	-1.9
A. # w/FOB test in past 2 yrs	5	2.0	7	3.1	-1.1	5	2.4	-0.3
B. # w/ rectal exam in past 2 yrs	0	0.0	2	0.9	-0.9	3	1.4	-1.4
Total Female User Pop 52 and older	507		457			423		
# w/screening	106	20.9	119	26.0	-5.1	86	20.3	+0.6
A. # w/FOB test in past 2 yrs	12	2.4	21	4.6	-2.2	18	4.3	-1.9
B. # w/ rectal exam in past 2 yrs	91	17.9	97	21.2	-3.3	71	16.8	+1.2

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Alcohol Screening (FAS Prevention)

Denominator(s):

GPRA Denominator: Female Active Clinical patients ages 15 to 44.

Female User Population patients ages 15 to 44.

Numerator(s):

Patients who have received any alcohol screen in the year prior to the end of the Report period.

A: Patients with any Alcohol Health Factor or other screening in prior year.

B: Patients with alcohol-related diagnoses in prior year.

C: Patients with alcohol-related patient education or counseling in prior year.

Ages are calculated at beginning of Report period. Screening is defined as at least one of the following: A1) Any Alcohol Health Factor A2) Screening diagnosis V11.3 (history of alcoholism), V79.1 (screening for alcoholism); B) Diagnosis (POV, current PCC or BHS Problem List): 303.\*, 305.0\*, 291.\*, 357.5\*; BHS diagnoses 10, 27, 29. C) Patient education codes containing "CD-"

During FY 2004, establish a baseline rate for alcohol use in female patients of child-bearing age.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical ages 15-44 (GPRA Denominator)	1,983		2,016			1,986		
# w/any alcohol screening (GPRA)	132	6.7	131	6.5	+0.2	125	6.3	+0.4
A. # w/alcohol health factor/other screening	76	3.8	36	1.8	+2.0	38	1.9	+1.9
B. # w/alcohol related diagnosis	56	2.8	90	4.5	-1.6	87	4.4	-1.6
C: # w/alcohol related patient education	41	2.1	12	0.6	+1.5	5	0.3	+1.8
Female User Population ages 15-44	2,689		2,656			2,613		
# w/any alcohol screening	137	5.1	136	5.1	-0.0	129	4.9	+0.2
A. # w/alcohol health factor or other screening	76	2.8	38	1.4	+1.4	39	1.5	+1.3
B. # w/alcohol related diagnosis	60	2.2	93	3.5	-1.3	90	3.4	-1.2
C: # w/alcohol related patient education	42	1.6	12	0.5	+1.1	5	0.2	+1.4

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Domestic Violence Screening

Denominator(s):

Female Active Clinical patients ages 13 and older.

GPRa Denominator: Female Active Clinical patients ages 16-24.

Female User Population patients ages 13 and older.

Numerator(s):

Patients screened for domestic violence at any time in the year prior to the end of the Report period.

A: Patients with documented IPV/DV exam.

B: Patients with IPV/DV related diagnoses.

C: Patients provided with education or counseling about Domestic Violence

Age is calculated at beginning of Report period. Screening is defined as at least one of the following: A) Exam code 34; B) Diagnosis (POV or current PCC or BHS Problem List): 995.80, 995.81, V15.41, V15.42, V15.49; BHS diagnoses 43.\*, 44.\* C1) Patient education codes containing "DV-"; C2) IPV/DV counseling: V61.11

For FY 2004, ensure that 15% of eligible women patients between the ages of 16 and 24 are screened for domestic violence at direct care facilities.

IHS FY 2004 Target: 15%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Female Active Clinical ages 13 and older	2,782		2,758			2,697		
# w/screening	39	1.4	56	2.0	-0.6	41	1.5	-0.1
A. # w/documented IPV/DV exam	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/ IPV/DV related diagnosis	37	1.3	55	2.0	-0.7	41	1.5	-0.2
C: # provided DV education	4	0.1	2	0.1	+0.1	0	0.0	+0.1
# Female Active Clinical ages 16-24 (GPRa Denominator)	729		744			729		
# w/screening (GPRa)	5	0.7	20	2.7	-2.0	12	1.6	-1.0
A. # w/ documented IPV/DV exam	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/ IPV/DV related diagnosis	4	0.5	20	2.7	-2.1	12	1.6	-1.1
C: # provided DV education	2	0.3	1	0.1	+0.1	0	0.0	+0.3

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Domestic Violence Screening (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Female User Pop 13 and older	3,691		3,597			3,520		
# w/screening	42	1.1	56	1.6	-0.4	42	1.2	-0.1
A. # w/ documented IPV/DV exam	0	0.0	0	0.0	+0.0	0	0.0	+0.0
B. # w/ IPV/DV related diagnosis	40	1.1	55	1.5	-0.4	42	1.2	-0.1
C: # provided DV education	5	0.1	2	0.1	+0.1	0	0.0	+0.1

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Prenatal HIV Testing

Denominator(s):

All pregnant female patients with no recorded HIV diagnosis in POV or problem list.

Numerator(s):

Patients who received counseling and/or patient education about HIV.  
 Patients who received HIV test during the year prior to the end of the Report period, including refusals.

A: Number of documented refusals.

Pregnancy is defined as at least two visits with POV V22.0-V23.9, 640-648, 651-676 during year prior to end of the Report period. HIV diagnosis: POV or Problem List codes 042.0-044.9, V08, or 795.71. HIV counseling: V65.44; or patient education codes containing "HIV-" or HIV diagnosis 042.0-044.9, V08, 795.71. HIV test: CPTs 86689, 86701-86703, 87390, 87391; LOINC taxonomy; site defined taxonomy BGP GPRA HIV TESTS; or Refusal XYZ Test HIV.

Increase the proportion of pregnant women screened for HIV during prenatal health care visits.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Pregnant Active Clinical w/ no HIV	229		243			201		
# w/HIV education	1	0.4	7	2.9	-2.4	1	0.5	-0.1
# w/HIV test	150	65.5	159	65.4	+0.1	43	21.4	+44.1
A. # test refusals	0	0.0	0	0.0	+0.0	1	0.5	-0.5

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Chlamydia Testing

Denominator(s):

Female Active Clinical patients ages 16 through 24.

Female User Population patients ages 16 through 24.

Numerator(s):

Patients tested for chlamydia in year prior to end of Report period.

Age is calculated at beginning of Report period. Chlamydia test defined as: V73.88, V73.98; CPT 87110, 87270, 87320, 87485-87, 87490-92, 87810; site-defined taxonomy BGP GPRA CHLAMYDIA TESTS; LOINC taxonomy

Increase the proportion of female patients ages 16 through 24 who have annual chlamydia screening.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical ages 16-24	729		744			729		
#/Chlamydia Screen	74	10.2	0	0.0	+10.2	0	0.0	+10.2
Female User Population ages 16-24	1,022		1,006			996		
# w/Chlamydia Screen	77	7.5	0	0.0	+7.5	0	0.0	+7.5

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Obesity Assessment

Denominator(s):

GPRA Denominator: All Active Clinical patients ages 2 through 74.

All User Population patients ages 2 through 74.

Numerator(s):

Patients for whom a BMI could be calculated

For those with a BMI calculated, patients considered overweight but not obese using BMI and standard tables.

For those with a BMI calculated, patients considered obese using BMI and standard tables.

Total of overweight and obese.

Age is calculated at beginning of the Report period. GPRA+ calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report period. For 19 through 50, height and weight must be recorded with last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2-18, definitions based on standard tables.

For FY 2004, establish a baseline rate for BMI available for children and adults.

BMI Available: IHS FY 2004: Goal: 50%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Users ages 2-74								
(GPRA Denominator)	5,682		5,643			5,543		
# w/BMI calculated (GPRA)	2,320	40.8	2,350	41.6	-0.8	2,090	37.7	+3.1
# overweight	468	8.2	521	9.2	-1.0	446	8.0	+0.2
# Obese	1,175	20.7	1,141	20.2	+0.5	983	17.7	+2.9
# Overweight/Obese	1,643	28.9	1,662	29.5	-0.5	1,429	25.8	+3.1

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Obesity Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Male Active Clinical users ages 2-74	2,186		2,190			2,168		
# w/BMI calculated	851	38.9	867	39.6	-0.7	784	36.2	+2.8
# overweight	145	6.6	167	7.6	-1.0	163	7.5	-0.9
# Obese	431	19.7	414	18.9	+0.8	337	15.5	+4.2
# Overweight/Obese	576	26.3	581	26.5	-0.2	500	23.1	+3.3
Female Active Clinical users ages 2-74	3,496		3,453			3,375		
# w/BMI calculated	1,469	42.0	1,483	42.9	-0.9	1,306	38.7	+3.3
# overweight	323	9.2	354	10.3	-1.0	283	8.4	+0.9
# Obese	744	21.3	727	21.1	+0.2	646	19.1	+2.1
# Overweight/Obese	1,067	30.5	1,081	31.3	-0.8	929	27.5	+3.0
# User Population Patients ages 2-74	8,056		7,920			7,762		
# w/BMI calculated	2,669	33.1	2,687	33.9	-0.8	2,436	31.4	+1.7
# overweight	556	6.9	589	7.4	-0.5	533	6.9	+0.0
# Obese	1,324	16.4	1,285	16.2	+0.2	1,128	14.5	+1.9
# Overweight/Obese	1,880	23.3	1,874	23.7	-0.3	1,661	21.4	+1.9
# Male User Pop 2-74 years	3,386		3,344			3,279		
# w/BMI calculated	1,044	30.8	1,040	31.1	-0.3	961	29.3	+1.5
# overweight	190	5.6	200	6.0	-0.4	208	6.3	-0.7
# Obese	523	15.4	497	14.9	+0.6	411	12.5	+2.9
# Overweight/Obese	713	21.1	697	20.8	+0.2	619	18.9	+2.2
# Female User Pop Patients 2-74 yrs	4,670		4,576			4,483		
# w/BMI calculated	1,625	34.8	1,647	36.0	-1.2	1,475	32.9	+1.9
# overweight	366	7.8	389	8.5	-0.7	325	7.2	+0.6
# Obese	801	17.2	788	17.2	-0.1	717	16.0	+1.2
# Overweight/Obese	1,167	25.0	1,177	25.7	-0.7	1,042	23.2	+1.7

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Obesity Assessment (con't)

	TOTAL ACTIVE CLINICAL POPULATION							
	Age Distribution							
	2-5	6-11	12-19	20-24	25-34	35-44	45-54	55-74
CURRENT REPORT PERIOD								
Total # Active Clin	646	695	955	633	1,032	800	530	391
# w/ BMI calculated	296	304	434	344	435	260	163	84
% w/BMI calculated	45.8	43.7	45.4	54.3	42.2	32.5	30.8	21.5
# Overweight	53	39	85	84	98	53	32	24
% Overweight	17.9	12.8	19.6	24.4	22.5	20.4	19.6	28.6
# Obese	86	113	181	193	273	173	112	44
% Obese	29.1	37.2	41.7	56.1	62.8	66.5	68.7	52.4
# Overweight or Obese	139	152	266	277	371	226	144	68
% Overweight or Obese	47.0	50.0	61.3	80.5	85.3	86.9	88.3	81.0
PREVIOUS YEAR PERIOD								
Total # Active Clin	625	713	947	655	1,050	791	503	359
# w/ BMI calculated	282	353	444	354	407	272	139	99
% w/BMI calculated	45.1	49.5	46.9	54.0	38.8	34.4	27.6	27.6
# Overweight	53	60	86	105	100	56	26	35
% Overweight	18.8	17.0	19.4	29.7	24.6	20.6	18.7	35.4
# Obese	66	143	182	184	247	174	96	49
% Obese	23.4	40.5	41.0	52.0	60.7	64.0	69.1	49.5
# Overweight or Obese	119	203	268	289	347	230	122	84
% Overweight or Obese	42.2	57.5	60.4	81.6	85.3	84.6	87.8	84.8
CHANGE FROM PREV YR %								
w/ BMI calculated	+0.7	-5.8	-1.4	+0.3	+3.4	-1.9	+3.1	-6.1
Overweight	-0.9	-4.2	+0.2	-5.2	-2.0	-0.2	+0.9	-6.8
Obese	+5.6	-3.3	+0.7	+4.1	+2.1	+2.6	-0.4	+2.9
Overweight or Obese	+4.8	-7.5	+0.9	-1.1	+0.0	+2.4	+0.6	-3.9
BASELINE REPORT PERIOD								
Total # Active Clin	601	705	934	667	1,079	763	468	326
# w/ BMI calculated	283	321	419	327	358	223	96	63
% w/BMI calculated	47.1	45.5	44.9	49.0	33.2	29.2	20.5	19.3
# Overweight	46	45	86	92	90	43	27	17
% Overweight	16.3	14.0	20.5	28.1	25.1	19.3	28.1	27.0
# Obese	62	125	177	171	204	146	60	38
% Obese	21.9	38.9	42.2	52.3	57.0	65.5	62.5	60.3
# Overweight or Obese	108	170	263	263	294	189	87	55
% Overweight or Obese	38.2	53.0	62.8	80.4	82.1	84.8	90.6	87.3
CHANGE FROM BASE YR %								
w/ BMI calculated	-1.3	-1.8	+0.6	+5.3	+9.0	+3.3	+10.2	+2.2
Overweight	+1.7	-1.2	-0.9	-3.7	-2.6	+1.1	-8.5	+1.6
Obese	+7.1	-1.8	-0.5	+3.8	+5.8	+1.1	+6.2	-7.9
Overweight or Obese	+8.8	-3.0	-1.5	+0.1	+3.2	+2.2	-2.3	-6.3

**SAMPLE GPRA+ FY04 SELECTED INDICATORS REPORT (All Indicators)**

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Obesity Assessment (con't)

	MALE ACTIVE CLINICAL POPULATION							
	Age Distribution							
	2-5	6-11	12-19	20-24	25-34	35-44	45-54	55-74
CURRENT REPORT PERIOD								
Total MALE Active Clin	333	328	420	175	337	297	180	116
# w/ BMI calculated	153	144	189	73	114	97	60	21
% w/BMI calculated	45.9	43.9	45.0	41.7	33.8	32.7	33.3	18.1
# Overweight	22	19	27	19	22	17	12	7
% Overweight	14.4	13.2	14.3	26.0	19.3	17.5	20.0	33.3
# Obese	47	56	81	44	79	69	46	9
% Obese	30.7	38.9	42.9	60.3	69.3	71.1	76.7	42.9
# Overweight or Obese	69	75	108	63	101	86	58	16
% Overweight or Obese	45.1	52.1	57.1	86.3	88.6	88.7	96.7	76.2
PREVIOUS YEAR PERIOD								
Total MALE Active Clin	323	348	423	192	341	293	161	109
# w/ BMI calculated	145	190	180	82	108	99	42	21
% w/BMI calculated	44.9	54.6	42.6	42.7	31.7	33.8	26.1	19.3
# Overweight	26	23	25	29	21	24	8	11
% Overweight	17.9	12.1	13.9	35.4	19.4	24.2	19.0	52.4
# Obese	36	86	81	42	71	61	30	7
% Obese	24.8	45.3	45.0	51.2	65.7	61.6	71.4	33.3
# Overweight or Obese	62	109	106	71	92	85	38	18
% Overweight or Obese	42.8	57.4	58.9	86.6	85.2	85.9	90.5	85.7
CHANGE FROM PREV YR %								
w/ BMI calculated	+1.1	-10.7	+2.4	-1.0	+2.2	-1.1	+7.2	-1.2
Overweight	-3.6	+1.1	+0.4	-9.3	-0.1	-6.7	+1.0	-19.0
Obese	+5.9	-6.4	-2.1	+9.1	+3.6	+9.5	+5.2	+9.5
Overweight or Obese	+2.3	-5.3	-1.7	-0.3	+3.4	+2.8	+6.2	-9.5
BASELINE REPORT PERIOD								
Total MALE Active Clin	306	350	429	204	362	284	139	94
# w/ BMI calculated	146	166	172	76	92	86	32	14
% w/BMI calculated	47.7	47.4	40.1	37.3	25.4	30.3	23.0	14.9
# Overweight	22	24	36	24	23	18	11	5
% Overweight	15.1	14.5	20.9	31.6	25.0	20.9	34.4	35.7
# Obese	35	55	76	39	55	54	18	5
% Obese	24.0	33.1	44.2	51.3	59.8	62.8	56.3	35.7
# Overweight or Obese	57	79	112	63	78	72	29	10
% Overweight or Obese	39.0	47.6	65.1	82.9	84.8	83.7	90.6	71.4
CHANGE FROM BASE YR %								
w/ BMI calculated	-1.8	-3.5	+4.9	+4.5	+8.4	+2.4	+10.3	+3.2
Overweight	-0.7	-1.3	-6.6	-5.6	-5.7	-3.4	-14.4	-2.4
Obese	+6.7	+5.8	-1.3	+9.0	+9.5	+8.3	+20.4	+7.1
Overweight or Obese	+6.1	+4.5	-8.0	+3.4	+3.8	+4.9	+6.0	+4.8

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Obesity Assessment (con't)

	FEMALE ACTIVE CLINICAL POPULATION							
	Age Distribution							
	2-5	6-11	12-19	20-24	25-34	35-44	45-54	55-74
CURRENT REPORT PERIOD								
Total FEMALE Active Clin	313	367	535	458	695	503	350	275
# w/ BMI calculated	143	160	245	271	321	163	103	63
% w/BMI calculated	45.7	43.6	45.8	59.2	46.2	32.4	29.4	22.9
# Overweight	31	20	58	65	76	36	20	17
% Overweight	21.7	12.5	23.7	24.0	23.7	22.1	19.4	27.0
# Obese	39	57	100	149	194	104	66	35
% Obese	27.3	35.6	40.8	55.0	60.4	63.8	64.1	55.6
# Overweight or Obese	70	77	158	214	270	140	86	52
% Overweight or Obese	49.0	48.1	64.5	79.0	84.1	85.9	83.5	82.5
PREVIOUS YEAR PERIOD								
Total FEMALE Active Clin	302	365	524	463	709	498	342	250
# w/ BMI calculated	137	163	264	272	299	173	97	78
% w/BMI calculated	45.4	44.7	50.4	58.7	42.2	34.7	28.4	31.2
# Overweight	27	37	61	76	79	32	18	24
% Overweight	19.7	22.7	23.1	27.9	26.4	18.5	18.6	30.8
# Obese	30	57	101	142	176	113	66	42
% Obese	21.9	35.0	38.3	52.2	58.9	65.3	68.0	53.8
# Overweight or Obese	57	94	162	218	255	145	84	66
% Overweight or Obese	41.6	57.7	61.4	80.1	85.3	83.8	86.6	84.6
CHANGE FROM PREV YR %								
w/ BMI calculated	+0.3	-1.1	-4.6	+0.4	+4.0	-2.3	+1.1	-8.3
Overweight	+2.0	-10.2	+0.6	-4.0	-2.7	+3.6	+0.9	-3.8
Obese	+5.4	+0.7	+2.6	+2.8	+1.6	-1.5	-4.0	+1.7
Overweight or Obese	+7.3	-9.5	+3.1	-1.2	-1.2	+2.1	-3.1	-2.1
BASELINE REPORT PERIOD								
Total FEMALE Active Clin	295	355	505	463	717	479	329	232
# w/ BMI calculated	137	155	247	251	266	137	64	49
% w/BMI calculated	46.4	43.7	48.9	54.2	37.1	28.6	19.5	21.1
# Overweight	24	21	50	68	67	25	16	12
% Overweight	17.5	13.5	20.2	27.1	25.2	18.2	25.0	24.5
# Obese	27	70	101	132	149	92	42	33
% Obese	19.7	45.2	40.9	52.6	56.0	67.2	65.6	67.3
# Overweight or Obese	51	91	151	200	216	117	58	45
% Overweight or Obese	37.2	58.7	61.1	79.7	81.2	85.4	90.6	91.8
CHANGE FROM BASE YR %								
w/ BMI calculated	-0.8	-0.1	-3.1	+5.0	+9.1	+3.8	+10.0	+1.8
Overweight	+4.2	-1.0	+3.4	-3.1	-1.5	+3.8	-5.6	+2.5
Obese	+7.6	-9.5	-0.1	+2.4	+4.4	-3.3	-1.5	-11.8
Overweight or Obese	+11.7	-10.6	+3.4	-0.7	+2.9	+0.5	-7.1	-9.3

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

#### Nutrition and Exercise Education

##### Denominator(s):

Active Clinical patients ages 6 and older considered overweight (including obese). Broken down by gender.

A: Active Clinical patients ages 6 and older considered obese. Broken down by age and gender.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

##### Numerator(s):

Patients provided with medical nutrition counseling in the year prior to end of Report period.

Patients provided specific nutrition education in the year prior to the end of the Report period.

Patients provided specific exercise education in year prior to end of Report period.

Patients provided with other related exercise and nutrition education.

Age of the patient is calculated at beginning of Report period. Overweight is defined as including both obese and overweight categories calculated by BMI. Overweight: Ages 19 and older, BMI equal to or greater than ( $\geq$ ) 25. Obese: Ages 19 and older, BMI equal to or greater than ( $\geq$ ) 30. For ages 18 and under, definition based on standard tables. GPRA+ calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Medical nutrition counseling defined as: CPT 97802-97804, G0270, G0271; Provider codes 07, 29, 97, 99; Clinic codes 67 (dietary) or 36 (WIC). Nutrition education defined as: POV V65.3 dietary surveillance and counseling; patient education codes ending "-N" (Nutrition) (or old code "-DT" (Diet)). Exercise education defined as: POV V65.41 exercise counseling; patient education codes ending "-EX" (Exercise). Related exercise and nutrition counseling defined as: patient education codes ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity).

Increase the proportion of at risk patients who are provided patient education on nutrition and exercise.

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Nutrition and Exercise Education (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# All Overweight Active Clinical patients =>6	1,504		1,543			1,321		
# w/medical nutrition counseling	70	4.7	35	2.3	+2.4	32	2.4	+2.2
# specific nutrition education provided	126	8.4	145	9.4	-1.0	65	4.9	+3.5
# w/exercise educ	51	3.4	53	3.4	-0.0	6	0.5	+2.9
# w/ other exec or nutrition educ	48	3.2	60	3.9	-0.7	4	0.3	+2.9
# Male All Overweight Active Clinical pts =>6	507		519			443		
# w/medical nutrition counseling	19	3.7	8	1.5	+2.2	5	1.1	+2.6
# specific nutrition education provided	32	6.3	37	7.1	-0.8	9	2.0	+4.3
# w/exercise educ	15	3.0	18	3.5	-0.5	1	0.2	+2.7
# w/ other exec or nutrition educ	13	2.6	16	3.1	-0.5	0	0.0	+2.6
# Female All Overweight Active Clinical pts =>6	997		1,024			878		
# w/medical nutrition counseling	51	5.1	27	2.6	+2.5	27	3.1	+2.0
# specific nutrition education provided	94	9.4	108	10.5	-1.1	56	6.4	+3.1
# w/exercise educ	36	3.6	35	3.4	+0.2	5	0.6	+3.0
# w/ other exec or nutrition educ	35	3.5	44	4.3	-0.8	4	0.5	+3.1

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

# Obese Active Clinical patients =>6	1,089		1,075			921		
# w/medical nutrition counseling	66	6.1	31	2.9	+3.2	27	2.9	+3.1
# specific nutrition education provided	110	10.1	120	11.2	-1.1	55	6.0	+4.1
# w/exercise educ	44	4.0	44	4.1	-0.1	4	0.4	+3.6
# w/ other exec or nutrition educ	38	3.5	50	4.7	-1.2	3	0.3	+3.2
# Male Obese Active Clinical pts =>6	384		378			302		
# w/medical nutrition counseling	18	4.7	7	1.9	+2.8	5	1.7	+3.0
# specific nutrition education provided	30	7.8	29	7.7	+0.1	8	2.6	+5.2
# w/exercise educ	14	3.6	13	3.4	+0.2	0	0.0	+3.6
# w/ other exec or nutrition educ	12	3.1	13	3.4	-0.3	0	0.0	+3.1
# Female Obese Active Clinical pts =>6	705		697			619		
# w/medical nutrition counseling	48	6.8	24	3.4	+3.4	22	3.6	+3.3
# specific nutrition education provided	80	11.3	91	13.1	-1.7	47	7.6	+3.8
# w/exercise educ	30	4.3	31	4.4	-0.2	4	0.6	+3.6
# w/ other exec or nutrition educ	26	3.7	37	5.3	-1.6	3	0.5	+3.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

# Active Diabetics	645		607			545		
# w/medical nutrition counseling	39	6.0	16	2.6	+3.4	41	7.5	-1.5
# specific nutrition education provided	121	18.8	124	20.4	-1.7	86	15.8	+3.0
# w/exercise educ	51	7.9	61	10.0	-2.1	12	2.2	+5.7
# w/ other exec or nutrition educ	22	3.4	38	6.3	-2.8	2	0.4	+3.0
# Male Active Diabetics	215		203			185		
# w/medical nutrition counseling	9	4.2	3	1.5	+2.7	12	6.5	-2.3
# specific nutrition education provided	32	14.9	36	17.7	-2.9	25	13.5	+1.4
# w/exercise educ	13	6.0	23	11.3	-5.3	1	0.5	+5.5
# w/ other exec or nutrition educ	6	2.8	16	7.9	-5.1	1	0.5	+2.3
# Female Active Diabetics	430		404			360		
# w/medical nutrition counseling	30	7.0	13	3.2	+3.8	29	8.1	-1.1
# specific nutrition education provided	89	20.7	88	21.8	-1.1	61	16.9	+3.8
# w/exercise educ	38	8.8	38	9.4	-0.6	11	3.1	+5.8
# w/ other exec or nutrition educ	16	3.7	22	5.4	-1.7	1	0.3	+3.4

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Nutrition and Exercise Education (con't)

## TOTAL OBESE ACTIVE CLINICAL POPULATION

## Age Distribution

	6-11	12-19	20-39	40-59	=>60
CURRENT REPORT PERIOD					
# Obese Active Clinical	113	181	554	210	31
# Med Nutr Educ	4	10	35	17	0
% w/Med Nutr Educ	3.5	5.5	6.3	8.1	0.0
# w/spec nutr educ	5	14	60	31	0
% w/spec nutr ed	125.0	140.0	171.4	182.4	0.0
# w/exercise educ	4	8	21	11	0
% w/exercise ed	100.0	80.0	60.0	64.7	0.0
# w/other educ	3	10	18	7	0
% w/other educ	75.0	100.0	51.4	41.2	0.0
PREVIOUS YEAR PERIOD					
# Obese Active Clinical	143	182	525	193	32
# Med Nutr Educ	5	7	14	3	2
% w/Med Nutr Educ	3.5	3.8	2.7	1.6	6.3
# w/spec nutr educ	14	21	51	28	6
% w/spec nutr ed	280.0	300.0	364.3	933.3	300.0
# w/exercise educ	3	5	21	13	2
% w/exercise ed	60.0	71.4	150.0	433.3	100.0
# w/other educ	4	10	22	14	0
% w/other educ	80.0	142.9	157.1	466.7	0.0
CHANGE FROM PREV YR %					
Med Nutr Educ	+0.0	+1.7	+3.7	+6.5	-6.3
Spec nutr ed	-155.0	-160.0	-192.9	-751.0	-300.0
w/exercise ed	+40.0	+8.6	-90.0	-368.6	-100.0
w/other educ	-5.0	-42.9	-105.7	-425.5	+0.0
BASELINE REPORT PERIOD					
# Obese Active Clinical	125	177	455	151	13
# Med Nutr Educ	2	3	13	8	1
% w/Med Nutr Educ	1.6	1.7	2.9	5.3	7.7
# w/spec nutr educ	4	7	29	12	3
% w/spec nutr ed	200.0	233.3	223.1	150.0	300.0
# w/exercise educ	1	0	3	0	0
% w/exercise ed	50.0	0.0	23.1	0.0	0.0
# w/other educ	0	0	3	0	0
% w/other educ	0.0	0.0	23.1	0.0	0.0
CHANGE FROM BASE YR %					
Med Nutr Educ	+1.9	+3.8	+3.5	+2.8	-7.7
Spec nutr ed	-75.0	-93.3	-51.6	+32.4	-300.0
w/exercise ed	+50.0	+80.0	+36.9	+64.7	+0.0
w/other educ	+75.0	+100.0	+28.4	+41.2	+0.0

**SAMPLE GPRA+ FY04 SELECTED INDICATORS REPORT (All Indicators)**

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Nutrition and Exercise Education (con't)

## MALE OBESE ACTIVE CLINICAL POPULATION

## Age Distribution

MALE Obese Active Clinical	6-11	12-19	20-39	40-59	=>60
CURRENT REPORT PERIOD					
MALE Obese Active Clinical	56	81	163	76	8
# Med Nutr Educ	3	3	7	5	0
% w/Med Nutr Educ	5.4	3.7	4.3	6.6	0.0
# w/spec nutr educ	3	5	15	7	0
% w/spec nutr ed	100.0	166.7	214.3	140.0	0.0
# w/exercise educ	3	3	6	2	0
% w/exercise ed	100.0	100.0	85.7	40.0	0.0
# w/other educ	3	4	2	3	0
% w/other educ	100.0	133.3	28.6	60.0	0.0
PREVIOUS YEAR PERIOD					
MALE Obese Active Clinical	86	81	147	58	6
# Med Nutr Educ	1	1	5	0	0
% w/Med Nutr Educ	1.2	1.2	3.4	0.0	0.0
# w/spec nutr educ	5	5	11	7	1
% w/spec nutr ed	500.0	500.0	220.0	0.0	0.0
# w/exercise educ	0	3	6	4	0
% w/exercise ed	0.0	300.0	120.0	0.0	0.0
# w/other educ	1	3	4	5	0
% w/other educ	100.0	300.0	80.0	0.0	0.0
CHANGE FROM PREV YR %					
Med Nutr Educ	+4.2	+2.5	+0.9	+6.6	+0.0
Spec nutr ed	-400.0	-333.3	-5.7	+140.0	+0.0
w/exercise ed	+100.0	-200.0	-34.3	+40.0	+0.0
w/other educ	+0.0	-166.7	-51.4	+60.0	+0.0
BASELINE REPORT PERIOD					
MALE Obese Active Clinical	55	76	129	41	1
# Med Nutr Educ	0	0	2	3	0
% w/Med Nutr Educ	0.0	0.0	1.6	7.3	0.0
# w/spec nutr educ	1	0	4	3	0
% w/spec nutr ed	0.0	0.0	200.0	100.0	0.0
# w/exercise educ	0	0	0	0	0
% w/exercise ed	0.0	0.0	0.0	0.0	0.0
# w/other educ	0	0	0	0	0
% w/other educ	0.0	0.0	0.0	0.0	0.0
CHANGE FROM BASE YR %					
Med Nutr Educ	+5.4	+3.7	+2.7	-0.7	+0.0
Spec nutr ed	+100.0	+166.7	+14.3	+40.0	+0.0
w/exercise ed	+100.0	+100.0	+85.7	+40.0	+0.0
w/other educ	+100.0	+133.3	+28.6	+60.0	+0.0

**SAMPLE GPRA+ FY04 SELECTED INDICATORS REPORT (All Indicators)**

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Nutrition and Exercise Education (con't)

## FEMALE OBESE ACTIVE CLINICAL POPULATION

## Age Distribution

FEMALE Obese Active Clinical	6-11	12-19	20-39	40-59	=>60
CURRENT REPORT PERIOD					
FEMALE Obese Active Clinical	57	100	391	134	23
# Med Nutr Educ	1	7	28	12	0
% w/Med Nutr Educ	1.8	7.0	7.2	9.0	0.0
# w/spec nutr educ	2	9	45	24	0
% w/spec nutr ed	200.0	128.6	160.7	200.0	0.0
# w/exercise educ	1	5	15	9	0
% w/exercise ed	100.0	71.4	53.6	75.0	0.0
# w/other educ	0	6	16	4	0
% w/other educ	0.0	85.7	57.1	33.3	0.0
PREVIOUS YEAR PERIOD					
FEMALE Obese Active Clinical	57	101	378	135	26
# Med Nutr Educ	4	6	9	3	2
% w/Med Nutr Educ	7.0	5.9	2.4	2.2	7.7
# w/spec nutr educ	9	16	40	21	5
% w/spec nutr ed	225.0	266.7	444.4	700.0	250.0
# w/exercise educ	3	2	15	9	2
% w/exercise ed	75.0	33.3	166.7	300.0	100.0
# w/other educ	3	7	18	9	0
% w/other educ	75.0	116.7	200.0	300.0	0.0
CHANGE FROM PREV YR %					
Med Nutr Educ	-5.3	+1.1	+4.8	+6.7	-7.7
Spec nutr ed	-25.0	-138.1	-283.7	-500.0	-250.0
w/exercise ed	+25.0	+38.1	-113.1	-225.0	-100.0
w/other educ	-75.0	-31.0	-142.9	-266.7	+0.0
BASELINE REPORT PERIOD					
FEMALE Obese Active Clinical	70	101	326	110	12
# Med Nutr Educ	2	3	11	5	1
% w/Med Nutr Educ	2.9	3.0	3.4	4.5	8.3
# w/spec nutr educ	3	7	25	9	3
% w/spec nutr ed	150.0	233.3	227.3	180.0	300.0
# w/exercise educ	1	0	3	0	0
% w/exercise ed	50.0	0.0	27.3	0.0	0.0
# w/other educ	0	0	3	0	0
% w/other educ	0.0	0.0	27.3	0.0	0.0
CHANGE FROM BASE YR %					
Med Nutr Educ	-1.1	+4.0	+3.8	+4.4	-8.3
Spec nutr ed	+50.0	-104.8	-66.6	+20.0	-300.0
w/exercise ed	+50.0	+71.4	+26.3	+75.0	+0.0
w/other educ	+0.0	+85.7	+29.9	+33.3	+0.0

**SAMPLE GPRA+ FY04 SELECTED INDICATORS REPORT (All Indicators)**

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Tobacco Use and Exposure Assessment

Denominator(s):

All Active Clinical patients ages 5 and older.

Pregnant female patients.

All User Population patients ages 5 and older.

Numerator(s):

Patients who have been screened for tobacco use in the year prior to the end of the Report period.

Patients identified as current tobacco users in prior year, both smokers and smokeless users.

A: Patients identified as current smokers in the past year.

B: Patients identified as current smokeless tobacco users in the past year.

Patients identified as exposed to environmental tobacco smoke (ETS) (second hand smoke) in the past year.

Ages are calculated at beginning of Report period. Pregnancy defined as at least two visits with POV or Problem diagnosis (V22.0-V23.9, 640.\*-648.\*, 651.\*-676.\*) during the year prior to the end of the Report period.

Tobacco screening is defined as at least one of the following: 1. Any health factor for category Tobacco documented in past year; 2.

Tobacco-related diagnoses (POV or current Active Problem List) 305.1\*, V15.82; 3. Dental code 1320; 4. Any patient education code containing "TO-" or "-TO". Tobacco users defined as: 1. Health Factors: Current

Smoker, Current Smokeless, Current Smoker and Smokeless; 2. Diagnosis codes 305.1\* or V15.82; 3. Dental code 1320. Smokers defined as: 1. Health Factors: Current Smoker or Current Smoker and Smokeless; 2. Diagnosis codes 305.1\* or V15.82; 3. Dental code 1320. Smokeless defined as: Health Factors: Current Smokeless or Current Smoker and Smokeless. ETS defined as: Health Factor Smoker in Home or Exposure to Environmental Tobacco Smoke

During FY 2004, establish a baseline rate for tobacco use screening.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Active Clinical Patients ages => 5 (GPRA Denominator)	9,486		8,209			7,483		
# w/Tobacco Screening (GPRA)	3,454	36.4	2,475	30.1	+6.3	2,551	34.1	+2.3
# tobacco users	1,789	18.9	1,384	16.9	+2.0	1,256	16.8	+2.1
A. # Smokers	1,736	18.3	1,381	16.8	+1.5	1,255	16.8	+1.5
B. # Smokeless Tobacco Users	60	0.6	7	0.1	+0.5	3	0.0	+0.6
# exposed to ETS/ smoker in home	31	0.3	5	0.1	+0.1	36	0.5	-0.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pregnant women	305		267			230		
# w/Tobacco Screening	149	48.9	107	40.1	+8.8	115	50.0	-1.1
# tobacco users	94	30.8	77	28.8	+2.0	79	34.3	-3.5
A. # Smokers	92	30.2	77	28.8	+1.3	79	34.3	-4.2
B. # Smokeless Tobacco Users	3	1.0	0	0.0	+1.0	0	0.0	+1.0
# exposed to ETS/smoker in home	2	0.7	0	0.0	+0.7	1	0.4	+0.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

# User Population ages =>5	7,469		7,362			7,232		
# w/Tobacco Screening	446	6.0	438	5.9	+0.0	469	6.5	-0.5
# tobacco users	171	2.3	170	2.3	-0.0	202	2.8	-0.5
A. # Smokers	166	2.2	169	2.3	-0.1	202	2.8	-0.6
B. # Smokeless Tobacco Users	5	0.1	1	0.0	+0.1	1	0.0	+0.1
# exposed to ETS/ smoker in home	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# Male User Pop patients => 5	3,078		3,048			3,010		
# w/Tobacco Screening	144	4.7	128	4.2	+0.5	154	5.1	-0.4
# tobacco users	66	2.1	63	2.1	+0.1	77	2.6	-0.4
A. # Smokers	63	2.0	63	2.1	-0.0	77	2.6	-0.5
B. # Smokeless Tobacco Users	3	0.1	0	0.0	+0.1	0	0.0	+0.1
# exposed to ETS/ smoker in home	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# Female User Pop patients => 5	4,391		4,314			4,222		
# w/Tobacco Screening	302	6.9	310	7.2	-0.3	315	7.5	-0.6
# tobacco users	105	2.4	107	2.5	-0.1	125	3.0	-0.6
A. # Smokers	103	2.3	106	2.5	-0.1	125	3.0	-0.6
B. # Smokeless Tobacco Users	2	0.0	1	0.0	+0.0	1	0.0	+0.0
# exposed to ETS/ smoker in home	0	0.0	0	0.0	+0.0	0	0.0	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

	TOTAL ACTIVE CLINICAL POPULATION					
	Age Distribution					
	5-13	14-17	18-24	25-44	45-64	65 and older
CURRENT REPORT PERIOD						
# Active Clinical	1,085	475	851	1,832	798	178
# Tobacco Screening	2	10	40	167	156	43
% w/Tobacco Screening	0.2	2.1	4.7	9.1	19.5	24.2
# Tobacco Users	0	4	14	78	51	8
% Tobacco Users	0.0	40.0	35.0	46.7	32.7	18.6
# Smokers	0	4	14	74	51	8
% Smokers	0.0	40.0	35.0	44.3	32.7	18.6
# Smokeless	0	0	0	4	0	0
% Smokeless	0.0	0.0	0.0	2.4	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0
PREVIOUS YEAR PERIOD						
# Active Clinical	1,113	465	878	1,841	755	154
# Tobacco Screening	2	10	42	167	151	36
% w/Tobacco Screening	0.2	2.2	4.8	9.1	20.0	23.4
# Tobacco Users	1	7	25	74	45	6
% Tobacco Users	50.0	70.0	59.5	44.3	29.8	16.7
# Smokers	1	7	25	73	45	6
% Smokers	50.0	70.0	59.5	43.7	29.8	16.7
# Smokeless	0	0	0	1	0	0
% Smokeless	0.0	0.0	0.0	0.6	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

	TOTAL ACTIVE CLINICAL POPULATION					
	Age Distribution					
	5-13	14-17	18-24	25-44	45-64	65 and older
CHANGE FROM PREV YR %						
Tobacco Screening	+0.0	-0.0	-0.1	+0.0	-0.5	+0.8
Tobacco Users	-50.0	-30.0	-24.5	+2.4	+2.9	+1.9
Smokers	-50.0	-30.0	-24.5	+0.6	+2.9	+1.9
Smokeless	+0.0	+0.0	+0.0	+1.8	+0.0	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
BASELINE REPORT PERIOD						
# Active Clinical	1,087	468	882	1,842	703	141
# Tobacco Screening	0	11	64	197	144	23
% w/Tobacco Screening	0.0	2.4	7.3	10.7	20.5	16.3
# Tobacco Users	0	6	29	91	51	7
% Tobacco Users	0.0	54.5	45.3	46.2	35.4	30.4
# Smokers	0	6	29	91	51	7
% Smokers	0.0	54.5	45.3	46.2	35.4	30.4
# Smokeless	0	0	0	0	1	0
% Smokeless	0.0	0.0	0.0	0.0	0.7	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0
CHANGE FROM BASE YR %						
Tobacco Screening	+0.2	-0.2	-2.6	-1.6	-0.9	+7.8
Tobacco Users	+0.0	-14.5	-10.3	+0.5	-2.7	-11.8
Smokers	+0.0	-14.5	-10.3	-1.9	-2.7	-11.8
Smokeless	+0.0	+0.0	+0.0	+2.4	-0.7	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

	MALE ACTIVE CLINICAL POPULATION					
	Age Distribution					
	5-13	14-17	18-24	25-44	45-64	65 and older
CURRENT REPORT PERIOD						
MALE Active Clinical	518	213	256	634	257	56
# Tobacco Screening	1	3	11	52	51	9
% w/Tobacco Screening	0.2	1.4	4.3	8.2	19.8	16.1
# Tobacco Users	0	2	5	26	20	2
% Tobacco Users	0.0	66.7	45.5	50.0	39.2	22.2
# Smokers	0	2	5	23	20	2
% Smokers	0.0	66.7	45.5	44.2	39.2	22.2
# Smokeless	0	0	0	3	0	0
% Smokeless	0.0	0.0	0.0	5.8	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0
PREVIOUS YEAR PERIOD						
MALE Active Clinical	544	217	266	634	239	44
# Tobacco Screening	1	2	12	56	33	11
% w/Tobacco Screening	0.2	0.9	4.5	8.8	13.8	25.0
# Tobacco Users	0	1	10	30	13	1
% Tobacco Users	0.0	50.0	83.3	53.6	39.4	9.1
# Smokers	0	1	10	30	13	1
% Smokers	0.0	50.0	83.3	53.6	39.4	9.1
# Smokeless	0	0	0	0	0	0
% Smokeless	0.0	0.0	0.0	0.0	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

## MALE ACTIVE CLINICAL POPULATION

## Age Distribution

5-13 14-17 18-24 25-44 45-64 65 and older

## CHANGE FROM PREV YR %

Tobacco Screening	+0.0	+0.5	-0.2	-0.6	+6.0	-8.9
Tobacco Users	+0.0	+16.7	-37.9	-3.6	-0.2	+13.1
Smokers	+0.0	+16.7	-37.9	-9.3	-0.2	+13.1
Smokeless	+0.0	+0.0	+0.0	+5.8	+0.0	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0

## BASELINE REPORT PERIOD

MALE Active Clinical	558	225	272	646	208	40
# Tobacco Screening	0	2	16	63	47	7
% w/Tobacco Screening	0.0	0.9	5.9	9.8	22.6	17.5
# Tobacco Users	0	1	9	33	18	3
% Tobacco Users	0.0	50.0	56.3	52.4	38.3	42.9
# Smokers	0	1	9	33	18	3
% Smokers	0.0	50.0	56.3	52.4	38.3	42.9
# Smokeless	0	0	0	0	0	0
% Smokeless	0.0	0.0	0.0	0.0	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0

## CHANGE FROM BASE YR %

Tobacco Screening	+0.2	+0.5	-1.6	-1.6	-2.8	-1.4
Tobacco Users	+0.0	+16.7	-10.8	-2.4	+0.9	-20.6
Smokers	+0.0	+16.7	-10.8	-8.2	+0.9	-20.6
Smokeless	+0.0	+0.0	+0.0	+5.8	+0.0	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

	FEMALE ACTIVE CLINICAL POPULATION					
	Age Distribution					
	5-13	14-17	18-24	25-44	45-64	65 and older
CURRENT REPORT PERIOD						
FEMALE Active Clinical	567	262	595	1,198	541	122
# Tobacco Screening	1	7	29	115	105	34
% w/Tobacco Screening	0.2	2.7	4.9	9.6	19.4	27.9
# Tobacco Users	0	2	9	52	31	6
% Tobacco Users	0.0	28.6	31.0	45.2	29.5	17.6
# Smokers	0	2	9	51	31	6
% Smokers	0.0	28.6	31.0	44.3	29.5	17.6
# Smokeless	0	0	0	1	0	0
% Smokeless	0.0	0.0	0.0	0.9	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0
PREVIOUS YEAR PERIOD						
FEMALE Active Clinical	569	248	612	1,207	516	110
# Tobacco Screening	1	8	30	111	118	25
% w/Tobacco Screening	0.2	3.2	4.9	9.2	22.9	22.7
# Tobacco Users	1	6	15	44	32	5
% Tobacco Users	100.0	75.0	50.0	39.6	27.1	20.0
# Smokers	1	6	15	43	32	5
% Smokers	100.0	75.0	50.0	38.7	27.1	20.0
# Smokeless	0	0	0	1	0	0
% Smokeless	0.0	0.0	0.0	0.9	0.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

## DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Tobacco Use and Exposure Assessment (con't)

## FEMALE ACTIVE CLINICAL POPULATION

## Age Distribution

5-13 14-17 18-24 25-44 45-64 65 and older

## CHANGE FROM PREV YR %

Tobacco Screening	+0.0	-0.6	-0.0	+0.4	-3.5	+5.1
Tobacco Users	-100.0	-46.4	-19.0	+5.6	+2.4	-2.4
Smokers	-100.0	-46.4	-19.0	+5.6	+2.4	-2.4
Smokeless	+0.0	+0.0	+0.0	-0.0	+0.0	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0

## BASELINE REPORT PERIOD

FEMALE Active Clinical	529	243	610	1,196	495	101
# Tobacco Screening	0	9	48	134	97	16
% w/Tobacco Screening	0.0	3.7	7.9	11.2	19.6	15.8
# Tobacco Users	0	5	20	58	33	4
% Tobacco Users	0.0	55.6	41.7	43.3	34.0	25.0
# Smokers	0	5	20	58	33	4
% Smokers	0.0	55.6	41.7	43.3	34.0	25.0
# Smokeless	0	0	0	0	1	0
% Smokeless	0.0	0.0	0.0	0.0	1.0	0.0
# Smokers receiving Cessation Counseling	0	0	0	0	0	0
% Smokers receiving Cessation Counseling	0.0	0.0	0.0	0.0	0.0	0.0
# ETS/Smk Home	0	0	0	0	0	0
% ETS/Smk Home	0.0	0.0	0.0	0.0	0.0	0.0

## CHANGE FROM BASE YR %

Tobacco Screening	+0.2	-1.0	-3.0	-1.6	-0.2	+12.0
Tobacco Users	+0.0	-27.0	-10.6	+1.9	-4.5	-7.4
Smokers	+0.0	-27.0	-10.6	+1.1	-4.5	-7.4
Smokeless	+0.0	+0.0	+0.0	+0.9	-1.0	+0.0
Counseling	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0
ETS	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Tobacco Cessation

Denominator(s):

Active Clinical patients identified as current tobacco users at least one year prior to end of Report period.

User Population patients identified as current tobacco users at least one year prior to end of Report period.

Numerator(s):

Patients who have received tobacco cessation counseling in year prior to the end of the Report period.

Patients counseled in prior year on smoking cessation medications.

Patients identified in prior year as quit tobacco use.

Tobacco users defined as documented in prior year: 1. Health Factors Current Smoker, Current Smokeless, Current Smoker and Smokeless; 2. Tobacco-related diagnoses 305.1\*, V15.82; 3. Dental code 1320. Tobacco cessation counseling defined as: 1. Patient education codes TO-QU (tobacco quit), TO-LA (tobacco lifestyle adaptation); 2. Clinic code 94 (tobacco cessation clinic); 3. Dental code 1320. Tobacco cessation medication counseling defined as: patient ed code TO-M. Quit tobacco use defined as: Health Factors documented in prior year: Cessation-Smoker, Cessation-Smokeless, Previous Smoker, Previous Smokeless.

For FY 2004, increase the percentage of patients identified as tobacco users who are counseled on quitting.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Tobacco Users	157		158			184		
# w/tobacco cessation counseling	7	4.5	1	0.6	+3.8	0	0.0	+4.5
# counseled on smoking cessation medications	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# who quit	2	1.3	1	0.6	+0.6	2	1.1	+0.2
User Population Tobacco Users	173		170			202		
# w/tobacco cessation counseling	11	6.4	1	0.6	+5.8	0	0.0	+6.4
# counseled on smoking cessation medications	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# who quit	2	1.2	1	0.6	+0.6	2	1.0	+0.2

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Cardiovascular Disease Prevention: Cholesterol Screening

Denominator(s):

All Active Clinical patients ages 23 through 70, broken down by gender.

All User Population patients ages 23 through 70, broken down by gender.

Numerator(s):

Patient with documented cholesterol screening any time in the five years prior to the end of the Report period.

Age is calculated at the beginning of the Report period. The difference between the age range 18-65 in the definition and 23-70 in the logic is because GPRA+ looks back 5 years for a test, i.e., when a patient who was 23 at the beginning of the Report period would have been 18. Counts all Y instances reported, regardless of the results of the measurement. Test definitions: Lipid Profile (panel): CPT 80061; POV V77.91 screening for lipid disorders; site-defined taxonomy DM AUDIT LIPID PROFILE TAX. Total Cholesterol: CPT 82465; LOINC taxonomy; site-defined taxonomy DM AUDIT CHOLESTEROL TAX.

Increase the proportion of adults ages 18 through 65 who have had their blood cholesterol checked within the preceding 5 years.

HP 1998 baseline: 67%; HP 2010 target: 80%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical users ages 23-70	2,963		2,950			2,911		
# w/ Cholesterol screening	1,142	38.5	1,118	37.9	+0.6	1,114	38.3	+0.3
# Male Active Clinical pop ages 23-70	988		985			976		
# w/ Cholesterol screening	409	41.4	415	42.1	-0.7	424	43.4	-2.0
# Female Active Clinical pop ages 23-70	1,975		1,965			1,935		
# w/ Cholesterol screening	733	37.1	703	35.8	+1.3	690	35.7	+1.5

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Cardiovascular Disease Prevention: Cholesterol Screening (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# User Population users ages 23-70	4,181		4,100			4,016		
# w/ Cholesterol screening	1,238	29.6	1,200	29.3	+0.3	1,200	29.9	-0.3
Total # of Male User Pop ages 23-70	1,608		1,589			1,550		
# w/ Cholesterol screening	467	29.0	456	28.7	+0.3	470	30.3	-1.3
Total # Female User Pop 23-70 yrs	2,573		2,511			2,466		
# w/ Cholesterol screening	771	30.0	744	29.6	+0.3	730	29.6	+0.4

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Cardiovascular Disease Prevention: Lipids Assessment

Denominator(s):

All Active Clinical patients ages 46 and over who are not diabetic (no diagnosis ever).

All User Population patients ages 46 and over who are not diabetic (no diagnosis ever)

Active Diabetic patients ages 46 and older, defined as all Active Clinical patients diagnosed with diabetes at least one year prior to the end of Report period, AND at least 2 visits in the past year, AND 2 DM-related visits ever.

Numerator(s):

Patients who have had either a LIPID PROFILE or an LDL, an HDL and Triglyceride (TG) (all three) in the 5 years prior to the end of the Report period.

Patients with LDL completed, regardless of result.

Patients with LDL <= 100

Patients with LDL 101-130

Patients with LDL 131-160

Patients with LDL > 160

Age of the patient is calculated at beginning of the Report period. For Denominator, no diabetes diagnosis ever (POV 250.00-250.93). For Numerators 1 and 2, counts all Y instances reported, regardless of the results of the measurement. For each of the tests described in the numerators, finds the last test done in the 5 years prior to the end of the Report period. Test Definitions: 1) Lipid Profile: CPT 80061; LOINC taxonomy; site defined taxonomy DM AUDIT LIPID PROFILE TAX. 2) LDL: CPT 83721; LOINC taxonomy; site defined taxonomy DM AUDIT LDL CHOLESTEROL TAX. 3) HDL: CPT 83718; LOINC taxonomy; site-defined taxonomy DM AUDIT HDL TAX. 4) Triglyceride: 84478; LOINC taxonomy; site defined taxonomy DM AUDIT TRIGLYCERIDE TAX.

For FY 2004, increase the proportion of patients ages 46 and older who have been assessed for dyslipidemia.

IHS FY03 Performance: TBD; HP 2010 Goal: 80%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients =>46 w/no DM DX	414		396			375		
# w/Lipid Profile OR TG&HDL&LDL recorded	188	45.4	177	44.7	+0.7	165	44.0	+1.4
# w/LDL done regardless of result	100	24.2	93	23.5	+0.7	84	22.4	+1.8
# w/LDL result =<100	30	7.2	25	6.3	+0.9	19	5.1	+2.2
# w/LDL result 101-130	38	9.2	34	8.6	+0.6	28	7.5	+1.7
# w/LDL result 131-160	16	3.9	13	3.3	+0.6	15	4.0	-0.1
# w/LDL result >160	5	1.2	4	1.0	+0.2	3	0.8	+0.4

**SAMPLE GPRA+ FY04 SELECTED INDICATORS REPORT (All Indicators)**

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Cardiovascular Disease Prevention: Lipids Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Male Active Clinical =>46 w/no DM DX	124		118			111		
# w/Lipid Profile OR TG & HDL & LDL recorded	55	44.4	53	44.9	-0.6	53	47.7	-3.4
# w/LDL done regardless of result	29	23.4	30	25.4	-2.0	26	23.4	-0.0
# w/LDL result =<100	10	8.1	8	6.8	+1.3	5	4.5	+3.6
# w/LDL result 101-130	10	8.1	8	6.8	+1.3	9	8.1	-0.0
# w/LDL result 131-160	7	5.6	8	6.8	-1.1	6	5.4	+0.2
# w/LDL result >160	0	0.0	0	0.0	+0.0	0	0.0	+0.0
Female Active Clinical =>46 w/no DM DX	290		278			264		
# w/Lipid Profile OR TG & HDL & LDL recorded	133	45.9	124	44.6	+1.3	112	42.4	+3.4
# w/LDL done regardless of result	71	24.5	63	22.7	+1.8	58	22.0	+2.5
# w/LDL result =<100	20	6.9	17	6.1	+0.8	14	5.3	+1.6
# w/LDL result 101-130	28	9.7	26	9.4	+0.3	19	7.2	+2.5
# w/LDL result 131-160	9	3.1	5	1.8	+1.3	9	3.4	-0.3
# w/LDL result >160	5	1.7	4	1.4	+0.3	3	1.1	+0.6

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Cardiovascular Disease Prevention: Lipids Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Population								
=>46 w/no DM DX	632		603			579		
# w/Lipid Profile OR TG&HDL&LDL recorded	205	32.4	193	32.0	+0.4	174	30.1	+2.4
# w/LDL done regardless of result	105	16.6	99	16.4	+0.2	89	15.4	+1.2
# w/LDL result =<100	30	4.7	25	4.1	+0.6	19	3.3	+1.5
# w/LDL result 101-130	40	6.3	35	5.8	+0.5	28	4.8	+1.5
# w/LDL result 131-160	16	2.5	13	2.2	+0.4	15	2.6	-0.1
# w/LDL result >160	6	0.9	6	1.0	-0.0	5	0.9	+0.1
Male User Population								
=> 46 w/no DM DX	234		224			217		
# w/Lipid Profile OR TG&HDL&LDL recorded	64	27.4	60	26.8	+0.6	57	26.3	+1.1
# w/LDL done regardless of result	31	13.2	31	13.8	-0.6	28	12.9	+0.3
# w/LDL result =<100	10	4.3	8	3.6	+0.7	5	2.3	+2.0
# w/LDL result 101-130	10	4.3	8	3.6	+0.7	9	4.1	+0.1
# w/LDL result 131-160	7	3.0	8	3.6	-0.6	6	2.8	+0.2
# w/LDL result >160	1	0.4	0	0.0	+0.4	1	0.5	-0.0
Female User Population								
=> 46 w/no DM DX	398		379			362		
# w/Lipid Profile OR TG&HDL&LDL recorded	141	35.4	133	35.1	+0.3	117	32.3	+3.1
# w/LDL done regardless of result	74	18.6	68	17.9	+0.7	61	16.9	+1.7
# w/LDL result =<100	20	5.0	17	4.5	+0.5	14	3.9	+1.2
# w/LDL result 101-130	30	7.5	27	7.1	+0.4	19	5.2	+2.3
# w/LDL result 131-160	9	2.3	5	1.3	+0.9	9	2.5	-0.2
# w/LDL result >160	5	1.3	6	1.6	-0.3	4	1.1	+0.2

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Cardiovascular Disease Prevention: Lipids Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Patients => 46	394		347			306		
# w/Lipid Profile OR TG&HDL&LDL recorded	352	89.3	311	89.6	-0.3	272	88.9	+0.5
# w/LDL done regardless of result	193	49.0	164	47.3	+1.7	112	36.6	+12.4
# w/LDL result =<100	114	28.9	88	25.4	+3.6	42	13.7	+15.2
# w/LDL result 101-130	42	10.7	40	11.5	-0.9	29	9.5	+1.2
# w/LDL result 131-160	11	2.8	10	2.9	-0.1	18	5.9	-3.1
# w/LDL result >160	7	1.8	7	2.0	-0.2	3	1.0	+0.8
Male Active Diabetic => 46	123		111			94		
# w/Lipid Profile OR TG&HDL&LDL recorded	108	87.8	99	89.2	-1.4	88	93.6	-5.8
# w/LDL done regardless of result	60	48.8	51	45.9	+2.8	40	42.6	+6.2
# w/LDL result =<100	33	26.8	30	27.0	-0.2	16	17.0	+9.8
# w/LDL result 101-130	13	10.6	10	9.0	+1.6	10	10.6	-0.1
# w/LDL result 131-160	5	4.1	3	2.7	+1.4	5	5.3	-1.3
# w/LDL result >160	5	4.1	5	4.5	-0.4	0	0.0	+4.1
Female Active Diabetic Patients => 46	271		236			212		
# w/Lipid Profile OR TG&HDL&LDL recorded	244	90.0	212	89.8	+0.2	184	86.8	+3.2
# w/LDL done regardless of result	133	49.1	113	47.9	+1.2	72	34.0	+15.1
# w/LDL result =<100	81	29.9	58	24.6	+5.3	26	12.3	+17.6
# w/LDL result 101-130	29	10.7	30	12.7	-2.0	19	9.0	+1.7
# w/LDL result 131-160	6	2.2	7	3.0	-0.8	13	6.1	-3.9
# w/LDL result >160	2	0.7	2	0.8	-0.1	3	1.4	-0.7

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

---

Cardiovascular Disease Prevention: Blood Pressure Control

Denominator(s):

All Active Clinical patients ages 20 and over who are not diabetic (no diagnosis ever).

All User Population patients ages 20 and older who are not diabetic (no diagnosis ever)

Numerator(s):

Patients with Blood Pressure value documented at least twice in prior two years.

Patients with normal Blood Pressure (BP), defined as < 120/80, i.e., the mean systolic value is less than (<) 120 AND the mean diastolic value is less than (<) 80.

Patients with Pre Hypertension I BP, defined as => 120/80 and < 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 AND the mean diastolic value is equal to 80.

Patients with Pre Hypertension II BP, defined as => 130/80 and <140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 AND the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.

Patients with Stage 1 Hypertension Blood Pressure (BP), defined as => 140/90 and <160/100, i.e., the mean systolic value is equal to or greater than (=>) 140 and less than (<) 160 AND the mean diastolic value is equal to or greater than (=>) 90 and less than (<) 100.

Patients with Stage 2 Hypertension BP, defined as => 160/100, i.e., the mean systolic value is equal to or greater than (=>) 160 AND the mean

diastolic value is equal to or greater than (=>) 100.

Age of the patient is calculated at beginning of the Report period. The difference between the age range 18 and older in the definition and 20 and older in the logic is because GPRA+ looks back 2 years for BP values. For Denominator, no diabetes diagnosis ever (POV 250.00-250.93). For each of the numerators, GPRA+ uses the last 2 Blood Pressures documented on non-ER visits in the 2 years prior to the end of the Report period. The mean Systolic value is calculated by adding the last 2 systolic values and dividing by 2. The mean Diastolic value is calculated by adding the diastolic values from the last 2 blood pressures and dividing by 2. If the systolic and diastolic values do not BOTH meet the current category, then the value that is least controlled determines the category.

For FY 2004, increase the proportion of patients ages 18 and older whose blood pressure has been assessed in past two years.

High Blood Pressure (=>140/90) Performance: HP 2010 Goal: 16%

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Cardiovascular Disease Prevention: Blood Pressure Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients								
ages 20 and older	2,507		2,544			2,556		
# w/ BPs documented	1,893	75.5	1,947	76.5	-1.0	1,960	76.7	-1.2
# w/Normal BP	981	39.1	1,001	39.3	-0.2	950	37.2	+2.0
# w/PRE HTN I BP	435	17.4	440	17.3	+0.1	478	18.7	-1.3
# w/PRE HTN II BP	322	12.8	337	13.2	-0.4	359	14.0	-1.2
# w/Stage 1 HTN BP	143	5.7	154	6.1	-0.3	158	6.2	-0.5
# w/Stage 2 HTN BP	12	0.5	15	0.6	-0.1	15	0.6	-0.1
Male Active Clinical Patients								
ages 20 and older	792		805			837		
# w/ BPs documented	555	70.1	552	68.6	+1.5	570	68.1	+2.0
# w/Normal BP	180	22.7	167	20.7	+2.0	164	19.6	+3.1
# w/PRE HTN I BP	156	19.7	153	19.0	+0.7	156	18.6	+1.1
# w/PRE HTN II BP	135	17.0	144	17.9	-0.8	162	19.4	-2.3
# w/Stage 1 HTN BP	80	10.1	82	10.2	-0.1	81	9.7	+0.4
# w/Stage 2 HTN BP	4	0.5	6	0.7	-0.2	7	0.8	-0.3
Female Active Clinical Patients								
ages 20 and older	1,715		1,739			1,719		
# w/ BPs documented	1,338	78.0	1,395	80.2	-2.2	1,390	80.9	-2.8
# w/Normal BP	801	46.7	834	48.0	-1.3	786	45.7	+1.0
# w/PRE HTN I BP	279	16.3	287	16.5	-0.2	322	18.7	-2.5
# w/PRE HTN II BP	187	10.9	193	11.1	-0.2	197	11.5	-0.6
# w/Stage 1 HTN BP	63	3.7	72	4.1	-0.5	77	4.5	-0.8
# w/Stage 2 HTN BP	8	0.5	9	0.5	-0.1	8	0.5	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Cardiovascular Disease Prevention: Blood Pressure Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop Patients ages 20 and older	3,815		3,777			3,732		
# w/ BPs documented	1,920	50.3	1,964	52.0	-1.7	1,973	52.9	-2.5
# w/Normal BP	995	26.1	1,009	26.7	-0.6	958	25.7	+0.4
# w/PRE HTN I BP	437	11.5	442	11.7	-0.2	480	12.9	-1.4
# w/PRE HTN II BP	329	8.6	342	9.1	-0.4	361	9.7	-1.0
# w/Stage 1 HTN BP	147	3.9	156	4.1	-0.3	159	4.3	-0.4
# w/Stage 2 HTN BP	12	0.3	15	0.4	-0.1	15	0.4	-0.1
Male User Pop Patients ages 20 and older	1,472		1,459			1,451		
# w/ BPs documented	566	38.5	560	38.4	+0.1	575	39.6	-1.2
# w/Normal BP	182	12.4	168	11.5	+0.8	166	11.4	+0.9
# w/PRE HTN I BP	156	10.6	154	10.6	+0.0	156	10.8	-0.2
# w/PRE HTN II BP	140	9.5	149	10.2	-0.7	164	11.3	-1.8
# w/Stage 1 HTN BP	84	5.7	83	5.7	+0.0	82	5.7	+0.1
# w/Stage 2 HTN BP	4	0.3	6	0.4	-0.1	7	0.5	-0.2
Female User Pop Patients ages 20 and older	2,343		2,318			2,281		
# w/ BPs documented	1,354	57.8	1,404	60.6	-2.8	1,398	61.3	-3.5
# w/Normal BP	813	34.7	841	36.3	-1.6	792	34.7	-0.0
# w/PRE HTN I BP	281	12.0	288	12.4	-0.4	324	14.2	-2.2
# w/PRE HTN II BP	189	8.1	193	8.3	-0.3	197	8.6	-0.6
# w/Stage 1 HTN BP	63	2.7	73	3.1	-0.5	77	3.4	-0.7
# w/Stage 2 HTN BP	8	0.3	9	0.4	-0.0	8	0.4	-0.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Hypertension Control

Denominator(s):

All Active Clinical patients ages 46 through 85 diagnosed with hypertension.

Numerator(s):

Number of patients with Blood Pressure value documented in past year. Patients with normal Blood Pressure (BP), defined as < 120/80, i.e., the mean systolic value is less than (<) 120 AND the mean diastolic value is less than (<) 80.

Patients with Pre Hypertension I BP, defined as => 120/80 and < 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 AND the mean diastolic value is equal to 80.

Patients with Pre Hypertension II BP, defined as => 130/80 and <140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 AND the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.

Patients with Stage 1 Hypertension Blood Pressure (BP), defined as => 140/90 and <160/100, i.e., the mean systolic value is equal to or greater than (=>) 140 and less than (<) 160 AND the mean diastolic value is equal to or greater than (=>) 90 and less than (<) 100.

Patients with Stage 2 Hypertension BP, defined as => 160/100, i.e., the mean systolic value is equal to or greater than (=>) 160 AND the mean diastolic value is equal to or greater than (=>) 100.

Age of the patient is calculated at beginning of the Report period. For Denominator, hypertension is defined as diagnosis (POV or problem list) 401.\* - 405.\* at least one year prior to end of Report period, and at least one hypertension POV during Report period.

For each of the numerators, GPRA+ uses the last 2 Blood Pressures documented on non-ER visits in the year prior to end of Report period. The mean Systolic value is calculated by adding the last 2 systolic values and dividing by 2. The mean Diastolic value is calculated by adding the diastolic values from the last 2 blood pressures and dividing by 2. If the systolic and diastolic values do not BOTH meet the current category, then the value that is least controlled determines the category.

For FY 2004, increase the proportion of hypertensive patients whose blood pressure is controlled, defined as <= 140/90.

REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
PERIOD		PERIOD		PREV YR	% PERIOD		BASE %

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

## Hypertension Control (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients								
ages 46 through 85								
w/Hypertension	378		314			284		
# w/ BPs documented	349	92.3	294	93.6	-1.3	261	91.9	+0.4
# w/Normal BP	83	22.0	71	22.6	-0.7	52	18.3	+3.6
# w/PRE HTN I BP	76	20.1	62	19.7	+0.4	59	20.8	-0.7
# w/PRE HTN II BP	94	24.9	60	19.1	+5.8	65	22.9	+2.0
# w/Stage 1 HTN BP	72	19.0	81	25.8	-6.7	67	23.6	-4.5
# w/Stage 2 HTN BP	24	6.3	20	6.4	-0.0	18	6.3	+0.0
Male Active Clinical Patients								
ages 46 to 85								
w/Hypertension	114		97			97		
# w/ BPs documented	109	95.6	87	89.7	+5.9	88	90.7	+4.9
# w/Normal BP	28	24.6	23	23.7	+0.9	15	15.5	+9.1
# w/PRE HTN I BP	21	18.4	18	18.6	-0.1	20	20.6	-2.2
# w/PRE HTN II BP	31	27.2	21	21.6	+5.5	26	26.8	+0.4
# w/Stage 1 HTN BP	25	21.9	20	20.6	+1.3	22	22.7	-0.8
# w/Stage 2 HTN BP	4	3.5	5	5.2	-1.6	5	5.2	-1.6
Female Active Clinical Patients								
ages 46 to 85								
w/Hypertension	264		217			187		
# w/ BPs documented	240	90.9	207	95.4	-4.5	173	92.5	-1.6
# w/Normal BP	55	20.8	48	22.1	-1.3	37	19.8	+1.0
# w/PRE HTN I BP	55	20.8	44	20.3	+0.6	39	20.9	-0.0
# w/PRE HTN II BP	63	23.9	39	18.0	+5.9	39	20.9	+3.0
# w/Stage 1 HTN BP	47	17.8	61	28.1	-10.3	45	24.1	-6.3
# w/Stage 2 HTN BP	20	7.6	15	6.9	+0.7	13	7.0	+0.6

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Cardiovascular Disease: Lipids Assessment

Denominator(s):

All patients diagnosed with cardiac disease at least one year prior to the end of the Report period and with at least two CVD-related visits any time in the previous year.

Numerator(s):

Number of patients with a LIPID PROFILE OR having an LDL and HDL and Triglyceride (TG) (all three).

Patients with LDL completed, regardless of result.

Patients with LDL <= 100

Patients with LDL 101-130

Patients with LDL 131-160

Patients with LDL > 160

Denominator: one visit at least one year prior to end of Report period AND 2 or more visits any time in the year prior to the end of the Report period with diagnosis of ischemic heart disease (Purpose of Visit 410.0-412.\*, 414.0-414.9, 428.\* or 429.2 recorded in the V POV file). For Numerators 1 and 2, counts all Y instances reported, regardless of the results of the measurement. For each of the tests described in the numerators, finds the last test done in the year prior to the end of the Report period. Test Definitions: 1) Lipid Profile: CPT 80061; LOINC taxonomy; site defined taxonomy DM AUDIT LIPID PROFILE TAX. 2) LDL: CPT 83721; LOINC taxonomy; site defined taxonomy DM AUDIT LDL CHOLESTEROL TAX. 3) HDL: CPT 83718; LOINC taxonomy; site-defined taxonomy DM AUDIT HDL TAX. 4) Triglyceride: 84478; LOINC taxonomy; site defined taxonomy DM AUDIT TRIGLYCERIDE TAX

Increase the proportion of patients with ischemic heart disease who had a lipids assessment and whose LDL result was good.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Patients w/ CVD DX	30		23			10		
# w/Lipid Profile OR TG & HDL & LDL recorded	20	66.7	17	73.9	-7.2	5	50.0	+16.7
# w/LDL done w or w/o result	5	16.7	8	34.8	-18.1	2	20.0	-3.3
LDL <=100	3	10.0	3	13.0	-3.0	2	20.0	-10.0
LDL 101-130	1	3.3	2	8.7	-5.4	0	0.0	+3.3
LDL 131-160	0	0.0	0	0.0	+0.0	0	0.0	+0.0
LDL >160	0	0.0	0	0.0	+0.0	0	0.0	+0.0

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Cardiovascular Disease: Lipids Assessment (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Male Patients								
w/ CVD DX	13		10			4		
# w/Lipid Profile OR TG & HDL & LDL recorded	10	76.9	9	90.0	-13.1	2	50.0	+26.9
# w/LDL done w or w/o result	4	30.8	4	40.0	-9.2	0	0.0	+30.8
LDL <=100	3	23.1	2	20.0	+3.1	0	0.0	+23.1
LDL 101-130	0	0.0	1	10.0	-10.0	0	0.0	+0.0
LDL 131-160	0	0.0	0	0.0	+0.0	0	0.0	+0.0
LDL >160	0	0.0	0	0.0	+0.0	0	0.0	+0.0
Female Patients								
w/ CVD DX	17		13			6		
# w/Lipid Profile OR TG & HDL & LDL recorded	10	58.8	8	61.5	-2.7	3	50.0	+8.8
# w/LDL done w or w/o result	1	5.9	4	30.8	-24.9	2	33.3	-27.5
LDL <=100	0	0.0	1	7.7	-7.7	2	33.3	-33.3
LDL 101-130	1	5.9	1	7.7	-1.8	0	0.0	+5.9
LDL 131-160	0	0.0	0	0.0	+0.0	0	0.0	+0.0
LDL >160	0	0.0	0	0.0	+0.0	0	0.0	+0.0

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

HIV Quality of Care

Denominator(s):

All patients ages 13 and older with at least 2 visits with HIV diagnosis within the service area (i.e., not Contract paid for) in the year prior to the end of the Report period, including 1 HIV diagnosis in last 6 months.

Numerator(s):

Patients who received CD4 test only (without HIV viral load) in the year prior to the end of the Report period.  
 Patients who received HIV viral load only (without CD4) in the year prior to the end of the Report period.  
 Patients who received both CD4 and HIV viral load in the prior year.  
 Total Numerators 1, 2 and 3.

Age is calculated at beginning of Report period. HIV diagnosis defined as: POV or Problem List 042.0-044.9, V08, or 795.71. XYZ test CD4 count defined as: CPT 86361, LOINC taxonomy and site defined taxonomy. HIV viral load, as measured by PCR or a comparable test: CPT 87536, 87539; LOINC taxonomy; and site-defined taxonomy

Increase the proportion of HIV-infected adolescents and adults who received testing consistent with current Public Health Service treatment guidelines.

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical >13 w/HIV DX	71		68			48		
# w/CD4 only	0	0.0	1	1.5	-1.5	0	0.0	+0.0
# w/viral load only	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# w/both	70	98.6	65	95.6	+3.0	47	97.9	+0.7
TOTAL # w/ tests	70	98.6	66	97.1	+1.5	47	97.9	+0.7

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Asthma

Denominator(s):

All Active Clinical patients.

A: All Active Clinical users under age 5.

B: All Active Clinical users ages 5 to 64.

C: All Active Clinical users ages 65 and older.

Numerator(s):

Patients who have had two asthma-related visits in the year prior to the end of the Report period or categorized in ARS as persistent.

Patients from Numerator 1 who have been hospitalized at any hospital for asthma in the year prior to the end of the Report period.

Age is calculated at beginning of Report period. Asthma visits are defined as diagnosis (POV) 493.\*. Persistent asthma is defined in ARS for Active patients as Severity 2, 3 or 4. Hospitalizations defined as service category H with primary admission diagnosis 493.\*.

Reduce percentage of asthmatic patients who are hospitalized for asthma.

Hospitalizations: HP 2010 Goal Under 5: 25 per 10,000; 5-64: 7.7 per 10,000; 65 and older: 11 per 10,000

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Total Active Clinical Patients	6,142		6,134			6,240		
# w/asthma	267	4.3	265	4.3	+0.0	253	4.1	+0.3
under 5	30	11.2	27	10.2	+1.0	28	11.1	+0.2
5-64	212	79.4	216	81.5	-2.1	214	84.6	-5.2
65 and older	25	9.4	22	8.3	+1.1	11	4.3	+5.0
# w/asthma hospitalization	21	7.9	13	4.9	+3.0	15	5.9	+1.9
under 5	4	19.0	2	15.4	+3.7	1	6.7	+12.4
5-64	13	61.9	10	76.9	-15.0	12	80.0	+18.1
65 and older	4	19.0	1	7.7	+11.4	2	13.3	+5.7

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Medications Education

Denominator(s):

All Active Clinical patients with Medications dispensed at their facility during the year prior to the end of the Report period.

All User Population patients with Medications dispensed at their facility during the year prior to the end of the Report period.

Numerator(s):

Patients who were provided patient education about their medications in any location.

Patients receiving medications are identified by any entry in the VMed file for your facility. Med education defined as: PFE code of M-I (medication information); M-DI (Drug interaction); M-FU (Medication follow up); M-L (Medication patient information literature) or any PFE code containing "-M".

Increase the proportion of patients taking medications who are receiving patient education about their medications.

HP 2010 Goal: 95%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Patients receiving medications	4,144		4,198			4,202		
# patients receiving medication educ	1,586	38.3	77	1.8	+36.4	43	1.0	+37.2
User Pop Patients receiving medications	4,745		4,813			4,826		
# patients receiving medication educ	1,644	34.6	79	1.6	+33.0	43	0.9	+33.8

\*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

Public Health Nursing

Denominator(s):

All User Population patients.

GPRA Indicator: Number of visits by PHNs in any setting.

- A. visits to patients age 0-28 days (Neonate).
- B. visits to patients age 29 days - 12 months (infants)
- C. visits to patients ages 1-64 years
- D. visits to patients aged 65 and older (Elders)

GPRA Indicator: Number of Home visits by PHNs in any setting.

- A. Home visits to patients age 0-28 days (Neonate)
- B. Home visits to patients age 29 days to 12 months (Infants)
- C. Home visits to patients ages 1-64 years
- D. Home visits to patients aged 65 and over (Elders).

Numerator(s):

For User Population only, the number of patients in the denominator served by PHNs in any setting.

The number of patients in the denominator served by PHNs in a HOME setting.

PHN visit is defined as any visit with primary or secondary provider code 13 or 32, or clinic 45. Home visits defined as clinic 11 or Location Home (as defined in Site Parameters) and a primary or secondary provider code 13 or 32.

During FY 2004, maintain the total number of public health nursing services (primary and secondary treatments and preventive services) provided to individuals in all settings at the FY 2003 workload levels.

IHS FY 2002 Performance: 383,436; IHS FY 2003 Performance: TBD

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR	BASE PERIOD	%	CHG from BASE
All User Population patients	8,626		8,509			8,378		
# patients served by PHNs in any Setting	1,212	14.1	1,625	19.1	-5.0	1,713	20.4	-6.3
# patients served by PHNs in a Home Setting	665	7.7	980	11.5	-3.8	1,073	12.8	-5.1

## \*\*\* IHS FY04 Clinical Performance Report \*\*\*

DEMO SITE

Report Period: Oct 01, 2002 to Sep 30, 2003

Previous Year Period: Oct 01, 2001 to Sep 30, 2002

Baseline Period: Oct 01, 2000 to Sep 30, 2001

-----  
Public Health Nursing (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR	BASE PERIOD	%	CHG from BASE
Total # PHN visits - any Setting	3,396		4,063		-667	4,626		-1,230
A. 0-28 days any Setting	36		37		-1	57		-21
B. 29d-12m any Setting	339		347		-8	315		+24
C. age 1-64 any Setting	2,670		3,482		-812	4,066		-1,396
D. age 65+ any Setting	351		197		+154	188		+163
Total # of PHN Visits - Home Setting	896		1,940		-1,044	2,128		-1,232
A. 0-28 days Home Setting	19		27		-8	43		-24
B. age 29d-12m Home Setting	142		201		-59	166		-24
C. age 1-64 Home Setting	664		1,592		-928	1,802		-1,138
D. age 65+ Home Setting	71		120		-49	117		-46